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1. Summary 
Neutrophils are among the most important components of the innate immune 
response, which provides the first line of host defense. The antimicrobial potential of 
neutrophils has been traditionally divided into either non-oxidative or oxidative 
mechanisms. Two of the most important antimicrobial systems of these mechansims 
are granule-associated antimicrobial proteases and peptides and the nicotinamid 
adenine dinucleotide phosphate (NADPH) oxidase generating reactive oxygen species 
(ROS). In the past, studies often focused on the effects of either non-oxidative or 
oxidative mechanisms and decades of research have provided a detailed 
understanding of the regulation, generation and actions of these processes alone. 
Recent evidence challenged the established view of two independent mechanisms and 
proposed the cooperation of the NADPH oxidase with granule proteases in the killing 
of microorganisms. Furthermore, a novel phagocytosis-independent antimicrobial 
mechanism was found by the discovery of neutrophil extracellular traps (NETs). The 
formation of NETs was found dependent on NADPH oxidase activation and the 
production of ROS but NETs are believed to kill entrapped pathogens by NETs-
associated granule proteases and peptides. Consequently, NETs present additional 
evidence for the interaction of non-oxidative and oxidative killing mechanisms.  
Together, these findings opened a new field of investigation with many controversies 
to be elucidated and underscored that we need further insight into the mechanisms by 
which neutrophils specifically recognize and overcome pathogens. 
 
In this thesis, we followed the question whether the murine antimicrobial peptide 
cathelin-related antimicrobial peptide (CRAMP) is an important component of the 
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non-oxidative arm of neutrophil defense against S. aureus. This was motivated 
because little is known about cathelicidin function and activity in neutrophils and 
seems of crucial interest since mice lack the major constituent of human neutrophils -
the -defensins. We further aimed to specify the relationship between the NADPH 
oxidase and CRAMP with focus on the antimicrobial activity of CRAMP in 
association with NETs and in NADPH oxidase-deficient mice (gp91phox-/-). As a 
result, we could demonstrate a previously unknown intracellular antimicrobial activity 
of CRAMP against S. aureus. Specifically, CRAMP colocalized with S. aureus in 
phagolysosomes and we showed first evidence for the presence of intracellular active 
CRAMP. Most interestingly, phagolysosomal localization and intracellular activity of 
CRAMP was found independent of a functional NADPH oxidase controversially to 
our expectations. Investigation of NET-dependent killing of S. aureus revealed a 
negligible role for CRAMP due to inactivation of the peptide in association with 
NETs. This point is of particular relevance and should be considered in the current 
opinion of NETs-mediated antimicrobial activity. In summary, our data provided 
deeper knowledge about one specific member of the non-oxidative killing mechanism 
and gives reason to reconsider the controversial results about interaction of NADPH 
oxidase in activating non-oxidative mechanisms. 
 
In addition, we followed the question whether recognition of S. aureus by TLR2 
regulates the induction of non-oxidative and oxidative killing responses as well as the 
induction of NETs. The background of this study is based on several previous reports. 
First, results of our group evidenced a relationship between TLR2-mediated 
staphylococcal killing by neutrophils and the susceptibility of S. aureus to cationic 
antimicrobial peptides. Additionally, TLR2 activation has been shown to up-regulate 
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cathelicidin expression. Second, TLR2 was demonstrated to induce phosphorylation 
of p47phox and up-regulation of p47phox mRNA in macrophages. However, little 
attention has been paid to similar studies in neutrophils. Third, recognition of 
pathogens by TLRs was hypothesized to induce formation of NETs but there is as yet 
no evidence. First results unraveled a role for TLR2 in rapid induction of the NADPH 
oxidase, whereas TLR2 signaling had no influence on CRAMP activity. Interestingly, 
pathogen sensing for the induction of NETs formation did not depend on TLR2-
MyD88 signaling. Taken together, the results demonstrate a role for TLR2 in 
mediating rapid killing of S. aureus by accelerating the activation of the NADPH 
oxidase complex possibly by influencing assembly. 
Further studies of the mechanisms underlying the relationship between pathogen 
sensing and non-oxidative and oxidative killing mechanisms would contribute greatly 
to our understanding of how the innate immune system resolves bacterial infections 
and will help in the development of therapeutic strategies to assist in clearance of 
pathogenic bacteria. 
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2. General Introduction 
2.1. Neutrophil Biology 
Neutrophils emerge from pluripotent hematopoietic stem cells in the bone marrow. 
They are released into the peripheral blood and circulate for 7-10 hours before 
migrating into the tissues, where they have a life span of only a few hours. 
Neutrophils leave the bone marrow as terminally differentiated cells synthesizing low 
amount of RNA and protein. In humans roughly 100 billion neutrophils enter and 
leave circulating blood every day. 
Neutrophils are the first immune cells recruited from the blood stream to the site of 
infection thereby building the first line of defense against invading microorganisms 
such as bacteria, fungi, and protozoa. The neutrophil-mediated inflammatory response 
is a multi-step process involving initial adhesion of circulating neutrophils to 
activated vascular endothelium, the subsequent extravasation and migration of 
neutrophils towards the site of infection and finally the elimination of invading 
microorganism. Most of these processes involve the mobilization of cytoplasmic 
granules and secretory vesicles. We here focus on the events involved in microbial 
clearance by neutrophil-mediated killing. On encountering the microbe, neutrophils 
take them up by phagocytosis. The phagosome fuses with cytoplasmic neutrophil 
granules to form a phagolysosome, wherein the bacteria are killed by non-oxidative 
and oxidative killing mechanisms. Non-oxidative killing is mediated by the 
antimicrobial arsenal stored in the neutrophil granules discussed in sections 2.1.1 and 
2.1.2, whereas oxidative killing depends on the generation of reactive oxygen species 
(ROS) described in section 2.1.3. 
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2.1.1. Neutrophil Granules 
Non-oxidative killing of invading pathogens is mediated by the fusion of neutrophil 
granules with the phagosome and the subsequent release of antimicrobial granule 
contents from the granule proteoglycan matrix into the phagolysosome. Four types of 
granules have been described and can be discriminated according to their protein 
contents (Figure 1). 
  
Figure 1. The four types of neutrophil granules. The contents of the neutrophil granule 
subsets encompass the non-oxidative killing mechanisms of neutrophils. Primary, secondary, 
and tertiary (gelatinase) granules, as well as secretory vesicles contain characteristic 
proteases, antimicrobial proteins, and receptors. CathG, cathepsin G; NE, neutrophil elastase; 
R, receptor; CR-1, complement receptor 1. Other abbreviations as explained in the text. 
Primary granules contain acidic hydrolases and antimicrobial proteins. 
Myeloperoxidase (MPO), the defining protein of primary granules (1-3), reacts with 
hydrogen peroxide (H2O2), formed by the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, to form hypochlorous acid (HOCl), which is highly 
toxic for microorganisms. MPO is released to the phagosome or the extracellular 
space upon neutrophil activation (4). In humans, the major constituents of primary 
granules are small cationic antimicrobial peptides named -defensins (5). -defensins 
have antimicrobial activity against a broad range of bacteria, fungi, enveloped viruses, 
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and protozoa (5-7). They exert antimicrobial function by forming multimeric 
transmembrane pores (8). Interestingly, murine granulocytes lack -defensins (9). In 
addition, primary granules contain three structurally related proteases: neutrophil 
elastase, cathepsin G, and proteinase-3 (10-12). Neutrophil elastase and cathepsin G 
double knock-out mice have a severe defect in clearance of infections (13) suggesting 
an important role of granule proteases in efficient microbial killing. Proteinase-3 is 
responsible for processing of the secondary granule protein human cathelicidin 
protein-18 (hCAP-18) into its antimicrobial active form LL-37 (14) indicating 
interaction of primary and secondary granule contents. 
The proteins of secondary granules encompass several potent AMPs including 
lactoferrin, hCAP-18 (human) and cathelin-related antimicrobial peptide (CRAMP, 
murine), neutrophil gelatinase-associated lipocalin (NGAL), and lysozyme. 
Lactoferrin and NGAL are iron-binding proteins and impair bacterial growth by iron 
sequestration (15-21). hCAP-18 and its murine homologue CRAMP are 18 kDa 
proteins belonging to the cathelicidin family of AMPs (22-25). The function of 
hCAP-18 and CRAMP will be discussed in detail in section 2.1.2. In addition to 
AMPs, the transmembrane units of NADPH oxidase gp91phox/p22phox (cytochrome 
b558) are constituent of the secondary granule membrane. It is recruited to the 
phagosome after neutrophil activation and initiates the oxidative burst (26, 27). 
In contrast to secondary granules with their high content of antimicrobials, gelatinase 
or tertiary granules contain the metalloproteases gelatinase (MMP-9) and leukolysin 
(MMP-25). They are stored as proforms and are proteolytically activated following 
exocytosis (28-32). The metalloproteases are believed to be of central importance in 
the degradation of vascular basement membranes during neutrophil extravasation due 
to degradation of extracellular matrix components (28, 33, 34). 
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The membranes of secretory vesicles comprise a reservoir of receptors, which are 
incorporated in the plasma membrane during exocytosis and are important in 
pathogen recognition: CD11b/CD18, complement receptor 1 (CR1), 
formylmethionyl-leucyl-phenylalanine (fMLP)-receptors, CD14, and the FcIII 
receptor CD16 (35-38). 
 
2.1.2. Cathelicidins of Men and Mice 
Cathelicidins are small cationic antimicrobial peptides (CAMPs). While human and 
mice each express a single cathelicidin, hCAP-18 and CRAMP respectively, other 
mammalians express several different cathelicidins. All cathelicidins are produced as 
inactive precursors consisting of an N-terminal signal peptide, a prosequence named 
cathelin (cathepsin L inhibitor) domain and a structurally variable C-terminal 
antimicrobial domain (Figure 2) (39). The signal peptide is cleaved off after targeting 
the cathelicidin to secondary granules. The 14 kDa cathelin domain is evolutionary 
highly conserved, whereas the C-terminal antimicrobial domain shows little sequence 
homology among species. The inactive 18 kDa proproteins are stored in the secondary 
granules of neutrophils (40). Proteolytic cleavage of the inactive precursor to release 
the active C-terminal antimicrobial peptide is mediated by proteinase-3 in humans and 
an unknown protease in mice upon neutrophil activation and degranulation (14). 
Intracellular cleavage and release of the mature peptide into the phagolysosome has 
not yet been found. The mature human peptide LL-37 has a length of 37 amino acids; 
the mature murine peptide CRAMP is 34 amino acids long. Both peptides have 
predicted amphipathic –helical structure and the mechanism of bactericidal activity 
assumes intercalation and assembly of the peptide within bacterial membranes to 
disrupt membrane integrity (41-44). 
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Figure 2. Schematic representation of CRAMP pre-proprotein and its processing site. 
The murine cathelicidin contains an N-terminal signal peptide, a highly conserved cathelin-
like domain in the middle and a highly variable C-terminal antimicrobial domain. 
In addition to neutrophils, hCAP-18 and CRAMP have been found in mast cells, 
macrophages, lymphocytes, and epithelial cells (45-49). In macrophages and 
epithelial cells, only low levels of cathelicidin are expressed but become strongly up-
regulated after infection or injury. Interestingly, the antimicrobial active form can be 
found in these cells, but how they are processed remains unknown. 
Purified or synthetic LL-37 and CRAMP have a broad range of antimicrobial activity 
against Gram-positive and Gram-negative bacteria. In vitro, Gram-negative bacteria 
are susceptible to lower concentrations of cathelicidin than Gram-positive bacteria. 
Lately, the generation of CRAMP-deficient mice underscored the importance of 
CRAMP against invading Gram-negative as well as Gram-positive pathogens in vivo. 
Experimental infection studies in CRAMP-deficient mice have demonstrated a critical 
role of CRAMP in defense against Streptococcus pyogenes skin infections (50), 
Escherichia coli urinary tract infections (51), and Neisseria meningitides bacteremia 
(52). So far, studies investigating the protective effect of cathelicidins mainly focused 
on epithelial cells and little is known about their function and activity in neutrophils. 
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2.1.3. The NADPH Oxidase 
As mentioned before, oxidative killing of invading pathogens depends on ROS 
generated by the NADPH oxidase. The NADPH oxidase is a multicomponent enzyme 
that transfers electrons from cytoplasmic NADPH onto extracellular or 
intraphagosomal molecular oxygen (O2), thereby generating superoxide (O2-). In 
resting cells, the NADPH oxidase is unassembled and inactive, with several protein 
components segregated into membrane and cytosolic locations. The membrane-bound 
subunits gp91phox and p22phox form the cytochrome b588. Cytochrome b588 is 
incorporated into the membranes of secondary granules and secretory vesicles in 
resting neutrophils, whereas the subunits p47phox, p67phox, p40phox, and Rac2 reside in 
the cytosol (Figure 3). During neutrophil activation and recruitment of secondary 
granules and secretory vesicles, cytochrome b588 locates to the phagolysosomal 
membrane or the cell surface. Then, the cytosolic p47phox is rapidly phosphorylated 
and the cytosolic subunits p47phox, p67phox, and p40phox translocate as a complex to the 
membrane (53-55). There, p47phox is further phosphorylated and associates with 
cytochrome b588. Additionally, p67phox interacts with cytochrome b588 and binds to the 
small GTPase Rac2, which translocated independently to the assembling oxidase (56-
58). The phosphorylation is assumed to be mediated by protein kinase C (PKC); 
however, several PKC isoforms have been found to phosphorylate p47phox (59-64). 
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Figure 3. Model illustrating the assembly of the NADPH oxidase. In resting neutrophils, 
the NADPH oxidase is unassembled and inactive. The subunits are segregated into membrane 
and cytosolic locations. Upon cell activation, the cytosolic regulatory components p47phox, 
p67phox, and p40phox translocate as a complex to the membrane-associated gp91phox/p22phox 
(cytochrome b558). The small GTPase Rac translocates independently to the assembling 
oxidase. 
Once assembled, the NADPH oxidase generates O2-. However, O2- itself has low 
bactericidal potency. Within the phagosome, superoxide is rapidly converted into 
H2O2 by superoxide dismutase (SOD). H2O2 reacts to form other ROS, such as singlet 
oxygen and hydroxyl radical (OH), which can efficiently kill bacteria. In addition, 
MPO can catalyze the H2O2-dependent oxidation of halides to form toxic hypohalous 
acids, mainly HOCl. The importance of NADPH oxidase is illustrated by the fact that 
persons who lack a functional oxidase have chronic granulomatous disease (CGD) 
and suffer from repeated life-threatening bacterial and fungal infections. In most cases 
of CGD the gene for gp91phox is mutated resulting in total absence of both gp91phox 
and p22phox (65-67). Interestingly, deficiency of MPO is common but seldom leads to 
serious defects in microbial killing questioning the importance of ROS in bacterial 
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clearance. Indeed, bactericidal activity of ROS is low when assessed under conditions 
found in the neutrophil phagolysosome (68). These findings raised doubts about the 
role of ROS in efficient microbial killing. 
Besides electron transfer, the NADPH oxidase also transfers protons to compensate 
for charge separation (69). Unexpectedly, the intraphagosomal pH does not decrease, 
but initially increases shortly after phagosome formation. Part of the charge 
compensation was shown to be due to influx of potassium ions instead of protons. 
Additionally, these cations were instrumental in liberating proteases from their acidic 
proteoglycan matrix in the granules (13). Thus, Segal and colleagues proposed the 
concept that the NADPH oxidase is primarily involved in the liberation of granule 
proteases into the phagosome. Their concept challenges the generally accepted view 
that oxidants directly confer microbial killing and needs to be further validated. 
However, this theory takes not into account the possibility that the activation of 
cathelicidin, which depends on active granule proteases, consequently might be 
affected as well. 
 
2.1.4. Neutrophil Extracellular Traps 
In 2004, a novel phagocytosis-independent killing mechanism, the formation of 
neutrophil extracellular traps (NETs), was discovered (70). In contrast to active 
phagocytosis and intracellular killing by AMPs and ROS, NETs provide an 
extracellular site for microbial killing. NETs consist of a backbone of nuclear 
chromatin-DNA that is decorated with AMPs and enzymes. Pathogens trapped by 
NETs are killed by high local concentrations of AMPs and enzymes similar to the 
killing in the phagolysosome; however, histones are also involved (71). 
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Lipopolysaccharide (LPS), phorbol myristate acetate (PMA), IL-8, and interferons 
have been shown to induce NETs to some extent as well as bacteria directly (70, 72, 
73). Pattern recognition receptors such as Fc receptors and Toll-like receptors 
(TLRs) are speculated to be involved in sensing and signaling and coincide to activate 
PKC, which induces assembly of the NADPH oxidase. Interestingly, the generation of 
ROS was found to be essential for NET induction (72). This ROS-mediated induction 
of NETs formation was termed NETosis (74) which points out that NETs are formed 
in a process that is neither apoptotic nor necrotic (75). However, the exact signaling 
events leading to NET formation are still unclear and need further investigation. 
NETs are able to entrap Gram-positive and Gram-negative bacteria as well as 
pathogenic fungi. Surprisingly, the mechanism of trapping has not yet been studied. 
Speculations about a charge-mediated mechanism whereby CAMPs in NETs trap 
negatively charged microbes exist. Consideration of the negative charge of the DNA 
backbone itself indicates that the positive net charge of CAMPs could also be 
neutralized by NETs-association alone. There is evidence that association of CAMPs 
with DNA reduces their bactericidal activity pointing towards neutralization of charge 
and thereby abolishing binding to the bacterial surface (76, 77). Consistently, no 
significant differences in the trapping by NETs of Streptococcus pneumoniae that had 
different surface charges were observed (78). It remains open what effectively 
attaches the microbe to NETs. 
Most bacteria are killed after they become trapped, but some bacteria are equipped 
with weapons against NETs. The most studied evasion mechanism is the production 
of an extracellular DNase for degradation of the DNA backbone. Other possible 
mechanisms might involve bacterial cell wall modifications to repel NETs or the 
 18
granule proteins, inhibition of NETs formation by blocking ROS, and secretion of 
proteases that degrade NET-associated granule proteins. 
 
2.2. Toll-like Receptors on Neutrophils 
Microbial infections are sensed by specific innate immune receptors, which recognize 
conserved patterns derived from pathogenic and non-pathogenic microbes. TLRs play 
a crucial role in the immediate detection and control of invading microbes. To date, 
11 mammalian and 13 murine TLRs have been described (79). TLRs are type I 
integral membrane glycoproteins characterized by the extracellular domains 
containing leucine-rich-repeat (LRR) motifs and a cytoplasmic signaling domain 
homologous to that of the interleukin 1 receptor, termed the Toll/IL-1R homology 
(TIR) domain. TLR1, 2, 4, 5, and 6 are expressed at the cell membrane whereas 
TLR7, 8, and 9 reside in subcellular compartments such as the endosome. Neutrophils 
express all of the TLRs with the exception of TLR3 (80). Individual TLRs recognize 
distinct microbe-associated molecular patterns (MAMPs) that have been evolutionary 
conserved in specific classes of microbes. The recognition of their unique ligands is 
mediated through diversification of LRR motifs, cooperative interactions between 
different TLRs, and the use of co-receptors or accessory molecules. 
Upon ligand binding, TLRs dimerize and undergo conformational changes. TLR2 was 
shown to form heterodimers with either TLR1 or TLR6 depending on the nature of 
the ligand (81). Conformational changes lead to the association of the TIR domains 
with either myeloid differentiation factor 88 (MyD88) or TIR domain-containing 
adaptor protein inducing interferon- (TRIF). MyD88 is critical for the signaling of 
all TLRs, except TLR3. Downstream signaling of MyD88 involves IL-1 receptor-
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associated kinase-4 (IRAK-4) and IRAK-1, which recruit tumor necrosis factor 
receptor-associated factor-6 (TRAF6). The cascade results in activation of nuclear 
factor-kappa B (NF-B) and mitogen-activated protein kinases to induce pro-
inflammatory genes and an antimicrobial response. TRIF signaling leads to the 
induction of a signaling cascade activating IRF-3 and IRF-7 and expression of type I 
interferons. 
 
2.3. Staphylococcus aureus 
Staphylococcus aureus is a facultative anaerobic Gram-positive bacterium colonizing 
the human skin and mucous membranes as a commensal. About 20% of the human 
population is persistently colonized, 60% are intermittent carriers, while 20% never 
carry the pathogen (82). When crossing the skin barrier, S. aureus causes abscess 
formation and has the possibility to disseminate and cause severe systemic infections. 
In the tissue, S. aureus is rapidly phagocytosed by neutrophils and exposed to the 
intracellular killing mechanisms described in the previous chapters. But, S. aureus is 
well equipped with several resistance mechanisms to survive in the phagosome. On 
the one hand, AMP resistance is due to natural modifications of teichoic acids and 
membrane phospholipids and secretion of proteases to disarm AMPs. On the other 
hand, S. aureus can resist oxidative killing by radical scavenging and removal of 
superoxide. 
Recognition of S. aureus by neutrophils inducing subsequent activation of 
antimicrobial defense and its resistance mechanisms against killing will be briefly 
outlined in the following sections. 
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2.3.1. Recognition of S. aureus by TLR2 
Sensing of S. aureus is mediated by staphylococcal lipoproteins and to a lesser extent 
by lipoteichoic acids, which are recognized by TLR2 and its co-molecules CD14 and 
CD36 (83-87). 
Activation of TLR2 by staphylococcal peptidoglycan and lipoproteins increased 
cathelicidin mRNA in murine fibroblasts (88) and cathelicidin protein in human 
corneal epithelial cells (89). The importance of TLR2 in mediating inflammatory and 
antimicrobial response against S. aureus is evidenced in TLR2-deficient mice, which 
are highly susceptible to S. aureus septicemia (90). Taken together, these results 
indicate a possible interaction between TLR2 and CAMP-mediated host defense. 
It remains to be elucidated whether TLR2 activates either a non-oxidative or oxidative 
antimicrobial response against S. aureus with further interest on the involvement of 
NADPH oxidase and the induction of NETs. 
 
2.3.2. Staphylococcal Resistance against AMPs 
Most neutrophil AMPs are of cationic nature. Staphylococcal resistance against 
CAMPs is therefore achieved by partially neutralizing the negative charge of the cell 
surface that would attract cationic molecules. The genes of the dltABCD operon insert 
positive charge modifications to wall teichoic acid and lipoteichoic acid. The Dlt 
proteins result in D-alanine substitutions of teichoic acid (91). Similarly, MprF adds 
L-lysine residues to phosphatidylglycerol exposed on the outer surface of the 
staphylococcal cytoplasmic membrane (92, 93). In both cases, the modifications 
reduce the affinity of CAMPs released into the phagosome and repel them from the 
cytoplasmic membrane. Staphylococcal mutants in dltA and mprF are highly 
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susceptible to killing by CAMPs and neutrophils in vitro, and show reduced virulence 
in animal infection models (94-96). In addition to positive charge modifications, 
S. aureus has the ability to neutralize CAMPs. Secretion of staphylokinase protects 
S. aureus from defensins due to its potent defensin-binding activity and aureolysin 
can inactivate LL-37 by cleavage (97, 98). 
 
 
Figure 4. Resistance mechanisms of S. aureus against killing by reactive oxygen species 
and antimicrobial peptides. Carotenoid pigment provides an antioxidant shield whereas 
catalase detoxifies hydrogen peroxide protecting S. aureus against ROS. Resistance to 
CAMPs is given by positive charge modifications of the cell wall, aureolysin-mediated 
proteolysis, and inactivation by staphylokinase. Modified from Nizet et al. (99). 
2.3.3. Staphylococcal Resistance against ROS 
ROS produced during the oxidative burst include superoxide anion, which is 
subsequently converted to H2O2, hydroxyl radical, and HOCl. Exogenously generated 
superoxide does not kill bacteria directly. S. aureus expresses two superoxide 
dismutases enzymes (SodA, SodM) responsible for removal of endogenous 
superoxide. There are contradictory results about the role of Sod in staphylococcal 
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resistance against superoxide in vivo. Clement et al. found evidence that inactivation 
of the major superoxide dismutase SodA has no effect on virulence in a mouse 
abscess model (100). A more recent study by the same group showed that mutants in 
SodA and SodM are less virulent in the mouse abscess model (101), indicating that 
SodA and SodM are involved in ROS resistance of S. aureus in vivo. H2O2 is 
bactericidal only at high concentrations. S. aureus can further convert H2O2 to H2O by 
the catalase KatA which accumulates extracelluarly protecting S. aureus from 
external H2O2 . In addition, S. aureus scavenges oxygen free radicals by expression of 
carotenoid pigment increasing resistance against oxidative neutrophil killing in vitro 
and in vivo (102). 
 
2.3.4. Staphylococcal Escape from NETs 
S. aureus can induce the formation of NETs and is itself entrapped in NETs pre-
activated with soluble stimuli (72, 75). Partial killing of S. aureus by NETs has been 
described but the killing activity was most likely due to the antimicrobial activity of 
histones and not granular proteins (75). Therefore, evasion of S. aureus from NETs 
must either depend on degradation of DNA backbone and escape from NETs or the 
inactivation of histones. Since S. aureus secretes a DNase similar to those described 
in NETs degradation by S. pneumoniae, this seems so far the most probable 
mechanisms for S. aureus to evade NETs. This interesting question has not yet been 
addressed and might be a future topic of our research. 
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3. Aim of Study 
Neutrophils are the first cells recruited to the site of infection providing immediate 
defense. Their relevance becomes obvious in persons who have neutrophils with 
defects in phagocytosis or killing and suffer from recurrent, often life-threatening 
infections. Neutrophils kill invading pathogens by a combination of non-oxidative and 
oxidative mechanisms involving antimicrobial peptides, reactive oxygen species and 
neutrophil extracellular traps. The microbicidal potential of many of these 
components alone is well established. First evidence of direct interaction of non-
oxidative and oxidative killing was given by the finding that the NADPH oxidase is 
involved in the liberation of granule proteases. However, it is not fully understood 
how these processes cooperate or depend on each other to kill bacteria. 
The first aim of this study was to examine the antimicrobial potential of neutrophil-
derived CRAMP and its site of action in staphylococcal killing. Further, the 
cooperation of non-oxidative and oxidative killing mechanisms was targeted with 
particular attention to the contributing roles of NETs and NADPH oxidase to 
cathelicidin-mediated host defense (Part 1). 
TLR2 contributes to efficient clearance of S. aureus by neutrophils and has been 
described to be involved in the regulation of antimicrobial peptide expression and in 
activation of the NADPH oxidase. Therefore, the second aim of the study was to 
investigate the role for TLR2 in cathelicidin-mediated staphylococcal killing and the 
potential regulation of CRAMP. Further, we intended to investigate the contribution 
of TLR2 in the oxidative killing of S. aureus and whether sensing of S. aureus by 
TLR2 induces the formation of NETs (Part 2). 
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Taken together, the aim of this thesis was to contribute to a better understanding of 
the complex network of non-oxidative and oxidative killing defense of neutrophils 
against S. aureus – on the one hand, by investigating the murine cathelicidin 
(CRAMP), its localization and site of action and on the other hand, by characterizing 
the TLR2-dependent regulation of non-oxidative and oxidative killing induced by 
S. aureus. 
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4. Results 
 
 27 
Part 1 
 
Neutrophil antimicrobial defense against Staphylococcus aureus is mediated 
by phagolysosomal and extracellular trap-associated cathelicidin 
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Abstract 
Neutrophils kill invading pathogens by antimicrobial peptides (AMPs) including 
cathelicidins, reactive oxygen species and neutrophil extracellular traps (NETs). The 
human pathogen Staphylococcus aureus exhibits enhanced resistance to neutrophil 
AMPs in part due to alanylation of teichoic acids by the dlt operon. In this study, we 
took advantage of the CRAMP-susceptible phenotype of S. aureus ∆dltA to study the 
impact of the murine cathelicidin CRAMP on staphylococcal killing and to identify 
its key site of action in murine neutrophils. 
We demonstrate that CRAMP remained intracellular during PMN exudation from 
blood and was secreted upon PMA stimulation. We show first evidence that CRAMP 
was recruited to phagolysosomes in infected neutrophils and exhibited intracellular 
activity against S. aureus. Later in infection, neutrophils produced NETs and 
immunofluorescence revealed association of CRAMP with S. aureus in NETs. NETs 
similarly killed both S. aureus wt and ∆dltA indicating that CRAMP activity was 
reduced when associated with NETs; CRAMP regained activity after DNase 
treatment. CRAMP localization in response to S. aureus was independent of the 
NADPH oxidase whereas killing was partially dependent. Our study unravels that 
neutrophils use CRAMP in a timed and locally coordinated manner in defense against 
S. aureus. 
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Introduction 
Antimicrobial peptides (AMPs) are widely distributed in animals and plants and are 
among the most ancient innate host defense factors. Mammalian AMPs include -
defensins, -defensins, and cathelicidins. Cathelicidins are found in several 
mammalian species and increasing evidence suggests a key role for cathelicidins in 
innate immune defense. Human and murine leukocytes each constitutively express a 
single cathelicidin: hCAP-18/LL-37 and CRAMP, respectively. hCAP-18/LL-37 and 
CRAMP are stored as pro-peptides in secondary granules of neutrophils. hCAP-18 is 
proteolytically cleaved to the antimicrobial form LL-37 by extracellular proteinase 3 
(1), while the processing protease of CRAMP is unknown. Additionally to leukocytes, 
various epithelia including keratinocytes can induce the production of cathelicidins 
after injury or infection (2). However, significant production of cathelicidin in 
keratinocytes takes several hours; neutrophils entering the injured or infected skin 
immediately, therefore confer a rapid first defense. 
In murine polymorphonuclear neutrophils (PMN), CRAMP is among the major 
cationic AMPs (CAMPs) due to a lack of -defensins in mice (3). The human and 
murine cathelicidins are strongly induced in response to Gram-positive and Gram-
negative species in vitro and in vivo (4-9). Lately, the generation of CRAMP-deficient 
mice made it possible to identify the importance of CRAMP against invading 
pathogens (10). Experimental infection studies in CRAMP-deficient mice have 
demonstrated a critical role of CRAMP in defense against Streptococcus pyogenes 
skin infections (11), Escherichia coli urinary tract infections (12), and Neisseria 
meningitidis bacteremia (4). 
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Recently, neutrophil extracellular traps (NETs) were described as a new 
phagocytosis-independent antimicrobial mechanism of PMN. NETs are composed of 
chromatin and specific enzymes and proteins from PMN granules. They are released 
in response to chemokines and microbial stimuli in a specialized form of cell death 
that depends upon the NADPH oxidase (13) providing a new linkage of oxidative 
burst and AMP function. Cathelicidins have been identified in similar extracellular 
traps released by mast cells (14) and D-alanyl modification of cell wall teichoic acid 
increased pneumococcal survival in NETs (15). 
Non-oxidative killing and oxidative killing pathways in PMN have long been 
considered independent of each other. During oxidative burst, specific granules 
containing the transmembrane component of the NADPH oxidase fuse with the 
forming phagosome accompanied by the activation of the oxidase complex through 
recruitment of cytosolic subunits to the central transmembrane core. The assembled 
NADPH oxidase transfers electrons from the cytosol to the phagosomal lumen, where 
they are used to generate superoxide ions, which together with myeloperoxidase 
promote microbial killing (16). Recent studies propose an additional role of K+ influx 
from the cytosol into the phagosomal lumen, promoting disaggregation of the granule 
proteoglycan matrix and activation of proteases including those responsible for 
processing of AMPs (17, 18). 
The crucial importance of NADPH oxidase in pathogen killing is evidenced in 
persons with chronic granulomatous disease (CGD) that bear inactivating mutations 
in genes of subunits of the oxidase complex and suffer from repeated life-threatening 
bacterial and fungal infection (19, 20). PMN of these patients exhibit normal 
degranulation but the initial phagosomal alkalization, which normally accompanies 
initiation of superoxide production, does not occur (21, 22). Additionally, correction 
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of phagocytic pH to more physiological values restores the ability of CGD neutrophils 
to kill S. aureus (22). Therefore, phagosomal alkalization was proposed to be essential 
for liberating granule enzymes in the phagosome (16). These observations suggest 
that granule proteases act in concert with oxidases for effective bacterial killing; 
however, the functional role of NADPH oxidase in AMP processing has not been 
studied. 
The major human pathogen S. aureus exhibits relative resistance to CAMPs due to 
positive-charge modifications to its cell wall such as peptidoglycan acetylation (23) 
and teichoic acid D-alanylation (24), the capacity to degrade CAMPs with specific 
proteases (25), and AMP-binding properties of staphylokinase (26). We had 
previously observed a reduced virulence of a S. aureus mutant with dealanylated 
teichoic acids (SA113 ∆dltA) in septic and local infection models (27, 28). This 
phenotype was tentatively correlated to an enhanced susceptibility to cathelicidin 
AMPs, but only through in vitro susceptibility testing (28). In order to more fully 
understand the potential role of CRAMP in the response to S. aureus infection, we 
here probe the regulation and cellular location of CRAMP expression in murine blood 
and exudate granulocytes. We further investigated the role of CRAMP in 
staphylococcal killing and its key site of action with particular attention to the 
contributing roles of NETs and NADPH oxidase to cathelicidin-mediated host 
defense. 
Our results demonstrated that PMN exert intracellular antimicrobial activity mediated 
by CRAMP against S. aureus. Additional extracellular entrapping and killing of S. 
aureus by NETs was partially mediated by CRAMP and may help to protect the host 
against further bacterial spreading and development of systemic disease. 
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Materials and Methods 
Bacterial strains. S. aureus wt (ATCC 35556, SA113 wt) and its isogenic mutants 
∆dltA, ∆spa, and ∆spa/∆dltA were grown overnight in tryptic soy broth (Difco) at 
37°C. For stimulation experiments, a subculture was inoculated 1:100 (v/v) from 
overnight culture in fresh tryptic soy broth and grown to late-log phase. Bacteria were 
washed twice with 0.9% NaCl prior to use. 
 
FITC-labeling of staphylococci. S. aureus subculture was grown to mid-log phase in 
fresh tryptic soy broth. Bacteria were washed twice with 0.9% NaCl and labeled in 
0.1 mg/ml FITC (Sigma) in PBS for 1h at 37°C with shaking. Prior to use, bacteria 
were washed twice with 0.9% NaCl and resuspended in Dulbecco’s PBS with 100 
mg/L MgCl2 and 100 mg/L CaCl2 (DPBS++, Invitrogen). 
 
Mice and tissue cage model. C57BL/6, CRAMP-/-, and gp91phox-/- mice were kept 
under specific pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital Basel, and University of California, San Diego, 
according to the regulations of the Swiss veterinary law and the Veterans 
Administration of San Diego Committee on Animal Use, respectively. Mice were 
euthanized by CO2 or i.p. injection of 500 mg/kg Thiopenthal (Abbott 
Laboratories). 
12-14-weeks-old female mice were anesthetized and sterile Teflon tissue cages were 
implanted subcutaneously, as described previously (28). Two weeks after surgery, the 
sterility of tissue cages was verified. To harvest tissue cage fluid (TCF) for isolation 
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of PMN, mice were anesthetized by isofluorane (MINRAD INC.) and TCF 
percutaneously collected with EDTA. 
 
Antibody generation. Two New Zealand White rabbits were immunized by 
repetitive subcutaneous injections of 150 µg synthetic CRAMP peptide (GL Shangai 
Biochem Ltd.) in adjuvant (MPL® + TDM + CWS Adjuvant System, Sigma) at 
monthly intervals. The titer of the antiserum was estimated by immunoblotting. The 
IgG fraction from the polyclonal anti-serum was isolated on a protein-G sepharose 
(Amersham) column and further affinity purified via affinity chromatography over a 
sepharose column (GE Healthcare) conjugated with synthetic CRAMP peptide used 
as immunogen. Bound antibody was eluted with 0.1 M glycin (0.002% sodium azide, 
pH 2.5) and dialyzed against PBS. A portion of the affinity-purified antibody was 
biotinylated as described previously (29), dialyzed against PBS and stored at -20°C. 
To demonstrate specificity, affinity-purified antibody was used to detect native 18 
kDa CRAMP from murine blood PMN lysates. Affinity-purified anti-CRAMP Ab 
was specific for one band of ~18 kDa, corresponding to the predicted size of pro-
CRAMP (Figure 2A). 
 
PMN isolation. For peripheral blood PMN (bPMN), mouse blood was harvested by 
intracardiac puncture in EDTA. bPMN were isolated as described previously for 
human PMN (30), but using a modified density gradient centrifugation on a 
discontinuous Percoll gradient with 59% and 67% Percoll (Amersham Biotech) in 
PBS. bPMN were collected at the interface of the two Percoll layers. 
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For peritoneal PMN (pPMN), 1 ml of 3% thioglycollate (BD Biosciences) were 
injected i.p. After 6h, pPMN were collected by peritoneal lavage with 5 ml RPMI 
1640 complete medium (5% FBS, 2 mM glutamate, 1 mM sodium pyruvate, 1.5 mM 
HEPES, non-essential amino acids) and pelleted by centrifugation. 
For TCF-PMN, TCF was collected in EDTA and pelleted by centrifugation. 
Where mentioned, bPMN, pPMN, and TCF-PMN were purified over a Percoll 
gradient as described above to a puritiy of > 97% (NIMP-R14 staining) and viability 
of PMN was 99% as assessed by trypan blue staining. 
 
Stimulation of PMN for flow cytometry and immunofluorescence. After isolation 
from blood, peritoneum, or TCF, erythrocytes were lysed in water and PMN were 
resuspended in DPBS++ at 1-2x106 cells/ml. PMN were incubated with 1 µg/ml PMA, 
unlabeled (for flow cytometry) or FITC-labeled (for immunofluorescence) SA113 
∆spa and SA113 ∆spa/∆dltA for 15 and 30 min at 37°C, 200 rpm. Stimulation was 
stopped on ice and PMN were collected by centrifugation for further use in flow 
cytometry or immunofluorescence. Supernatants were collected and released CRAMP 
was measured by ELISA. 
 
Immunofluorescence. After stimulation, cells were spun onto glass coverslips and 
fixed with 4% paraformaldehyde (PFA) in PBS for 30 min at room temperature (RT). 
After permeabilization with 0.2% saponin for 30 min at RT and 5 min in methanol, 
cells were blocked with 2% normal goat or donkey serum (NGS or NDS) for 30 min 
at RT. Cells were stained with affinity-purified rabbit anti-CRAMP (1 µg/ml), 
biotinylated rabbit anti-CRAMP (5 µg/ml), goat anti-cathepsin D (10 µg/ml, Santa 
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Cruz Biotechnology), and rabbit anti-LAMP-1 (10 µg/ml, Abcam) Ab, followed by 
donkey anti-rabbit/goat IgG-Cy3 Ab (7.5 µg/ml, Jackson ImmunoResearch) or 
Streptavidin-Alexa647 (10 µg/ml, Molecular Probes). Isotype-matched Ab served as 
negative controls. To confirm specificity of antibody binding, parallel slides were 
treated identically with affinity-purified rabbit anti-CRAMP Ab that had been 
preincubated for 1h at RT with 20 µg/ml synthetic CRAMP peptide which abolished 
staining (Figure 2B). Specimens were analyzed with a Zeiss Axiovert 100M 
microscope (Carl Zeiss AG) using the confocal system LSM 510 META and LSM 
510 v3.2 SP2 software (Zeiss). 
 
Flow cytometry. Cells were blocked with 2% NGS, fixed with 4% PFA, and 
permeabilized for intracellular staining with 0.1% saponin. Rat anti-mouse 
CD16/CD32 (Pharmingen) has been used to block Fc-receptor binding of IgG. After 
Fc-blocking, cells were sequentially stained with biotinylated rabbit anti-CRAMP Ab 
(1 µg/ml) and Streptavidin-RPE (0.25 µg/ml) or the neutrophil marker rat- anti mouse 
NIMP-R14 (10 µg/ml, own hybridoma) and FITC-conjugated goat anti-rat Ab (7.5 
µg/ml, Jackson ImmunoResearch). Biotinylated rabbit IgG and rat IgG2a 
(Pharmingen) were used as isotype controls. 
 
PMN killing assay. TCF-PMN were resuspended in DPBS++ (with 10% pooled 
mouse plasma) and 2x105 PMN were incubated with SA113 wt or ∆dltA at a 
multiplicity of infection (MOI) of 1 and incubated at 37°C, 200 rpm. After 2h, 
samples were diluted in H2O (pH 11) to lyse PMN and serial dilutions were plated on 
Mueller-Hinton agar (MHA) to enumerate surviving intra- and extracellular bacteria. 
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Intracellular killing assay. pPMN were resuspended at 1x106 PMN in RPMI 1640 
(10 mM HEPES, 2% pooled mouse plasma), seeded into 24-well plates and allowed 
to adhere for 1h. PMN were infected with SA113 wt and ∆dltA at a MOI of 1, 
centrifuged at 800 x g for 5 min to synchronize phagocytosis and further incubated at 
37°C and 5% CO2 for 10 min. 50 U lysostaphin was added for 10 min to kill 
extracellular bacteria. Immediately (0 min) and 30 min after lysostaphin treatment, 
PMN were lysed with H2O (pH 11) and serial dilutions were plated on MHA to assess 
surviving intracellular bacteria. Intracellular killing was calculated as the percentage 
of intracellular bacteria at 30 min versus 0 min. 
 
NET-dependent killing assay. pPMN were resuspended at 2x106 PMN in RPMI 
1640 (10 mM HEPES, 2% pooled mouse plasma), seeded into 24-well plates and 
activated with 50 nM PMA for 4h. The medium was carefully replaced with medium 
containing cytochalasin D (10 µM) with or without 50 U DNase1 to degrade NETs. 
Samples were infected with SA113 wt and ∆dltA at a MOI 0.01, centrifuged at 800 x 
g for 10 min and incubated at 37°C and 5% CO2 for 30 min. Wells were thoroughly 
scraped and serial dilutions were plated on MHA to assess surviving bacteria. NET-
dependent killing was calculated as percentage of bacteria incubated without 
neutrophils. 
 
Immunofluorescence of NETs. 2x105 bPMN or pPMN were seeded in poly-L-
lysine-covered 16-well glass chamber slides, allowed to settle and either treated with 
PMA (50 nM), SA113 ∆spa, SA113 ∆spa/∆dltA at a MOI of 10 or left unstimulated 
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for 4h. Cells were fixed with 4% PFA, blocked with 2% NGS, and stained with 
affinity-purified rabbit anti-CRAMP (1 µg/ml) and donkey anti-rabbit IgG-Cy3 (7.5 
µg/ml) Ab. Controls were done with isotype-matched Ab. For labeling of DNA, 
SYTOX® Green (1 µM, Molecular Probes) was used. Specimens were analyzed as 
described above in immunofluorescence. 
 
ELISA. An ELISA for CRAMP was developed using 96-well flat-bottom 
immunoplates (Nunc). Plates were coated overnight with 1 µg/ml affinity-purified 
rabbit anti-CRAMP Ab in 1 M carbonate buffer (pH 9.6) at 4°C. After blocking with 
1% casein in PBS, samples and standards were added and incubated for 2h. 
Biotinylated anti-CRAMP Ab (400 ng/ml) was added for 1h and further incubated 
with Streptavidin-HRP (Zymed). After incubation for 30 min with TMB substrate 
(Pharmingen), reaction was stopped with 1 M H2SO4 and absorbance was measured at 
450 nm. Between each step, plates were washed 4 times with PBS (0.05% Tween-20). 
All incubations were carried out at RT. 
 
Immunoblot analysis. 1x106 pPMN were infected for 15 min with SA113 wt or left 
unstimulated. Cells were then lysed in 0.9% NaCl containing 1% Triton X-100, 1 mM 
PMSF and a protease inhibitor cocktail (Roche). Cell lysates were separated by SDS-
PAGE and transferred to nitrocellulose membrane (Schleicher & Schüll). Membranes 
were blotted with affinity-purified rabbit anti-CRAMP Ab (1 µg/ml) followed by 
horseradish peroxidase conjugated donkey anti-rabbit IgG (0.16 µg/ml) and were 
visualized with enhanced chemiluminescence (Amersham Bioscience) on films 
(KODAK). 
  43 
 
Statistical analysis. PMN killing assay was analyzed with Mann-Whitney. Flow 
cytometry data, intracellular killing and NET-dependent killing assays were analyzed 
with paired student’s t-test. Statistical analysis was done with Prism 5.0a (GraphPad 
Software, Inc.). A p-value of p <0.05 was considered statistically significant. 
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Results 
PMN-derived CRAMP is active against S. aureus 
S. aureus is resistant to CRAMP due to a variety of mechanisms including D-
alanylation of teichoic acids (24). We sought to exploit the differential sensitivity of 
S. aureus (SA113) wt and its isogenic ∆dltA mutant to better understand the 
regulation, cellular localization and function of neutrophil-derived CRAMP. PMN 
from tissue cages (TCF-PMN) in C57BL/6 mice exhibited significantly increased 
bactericidal activity against SA113 ∆dltA compared to wt in vitro (Figure 1). In 
contrast, TCF-PMN from CRAMP-/- mice showed similar bactericidal activity against 
SA113 wt and ∆dltA. In addition, the bactericidal activity of CRAMP-/- TCF-PMN 
against SA113 wt was significantly lower than of C57BL/6 PMN (Figure 1). 
 
Figure 1. Bactericidal activity of TCF-PMN from C57BL/6 and CRAMP-/- mice. The numbers of 
viable CFU of SA113 wt (closed) and SA113 ∆dltA (open) after 2h of incubation with TCF-PMN in 
vitro are expressed as percentage of the initial inoculum. Data are mean ± SD of three independent 
experiments. Significant differences are indicated by *: p<0.05 and ***: p<0.001. 
These data showed that the susceptibility of SA113 ∆dltA to PMN is predominantly 
mediated by CRAMP; allowing the ∆dltA mutant to serve as a powerful tool to study 
CRAMP function and activity. Furthermore, the decreased bactericidal activity of 
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CRAMP-/- PMN implies that the expression of CRAMP in PMN is indeed important 
for the defense against S. aureus in vivo, despite the apparent resistance of the 
bacterium to the isolated AMP in vitro. 
 
Degranulation of CRAMP does not occur during PMN migration 
First, the specificity of affinity-purified rabbit anti-CRAMP Ab was tested by 
immunoblot analysis of blood PMN lysates. The antibody recognized a single band at 
~18 kDa corresponding to the predicted size of pro-CRAMP (Figure 2A). The anti-
CRAMP Ab was also specific for CRAMP in immunofluorescence as preincubation 
of anti-CRAMP Ab with excess synthetic CRAMP abolished staining on peritoneal 
PMN (Figure 2B). Next, we studied the location and the site of action of CRAMP by 
investigating intracellular CRAMP expression by flow cytometry in C57BL/6 PMN. 
To exclude that exudation from the bloodstream itself affects CRAMP expression, 
PMN purified from TCF and peritoneal exudates were compared to peripheral blood 
PMN. CRAMP was expressed intracellularly in PMN from all sites (Figure 2Ci-iii, 
upper row). Mean fluorescence intensity (MFI) was similar in all purified PMN 
indicating no loss of CRAMP during exudation from blood. Purified PMN were 
>97% positive for the granulocyte marker NIMP-R14 Ab as shown for TCF-PMN in 
Figure 2Aiv (upper row). Using fluorescence microscopy we showed that CRAMP is 
distributed in a granular pattern in PMN from blood, peritoneal cavity, and TCF 
(Figure 2Bi-iii, lower row). 
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Figure 2. Intracellular CRAMP expression in blood and exudate PMN. (A) Western blot analysis 
of bPMN lysates using affinity-purified rabbit anti-CRAMP Ab. (B) Intracellular staining of pPMN 
with rabbit anti-CRAMP Ab followed by Cy3-conjugated donkey anti-rabbit Ab (i) and identical 
staining performed with antibody preincubated with excess of synthetic CRAMP peptide (ii). (C, upper 
row) PMN purified from blood (i), peritoneal exudate (ii), and TCF (iii) from C57BL/6 mice were 
intracellularly stained with biotinylated rabbit anti-CRAMP (black) or isotype control (grey) Ab 
followed by RPE-conjugated Streptavidin and analyzed by flow cytometry. (iv) Purified TCF-PMN 
stained with the neutrophil marker NIMP-R14 (black) or isotype control (grey) Ab followed by FITC-
conjugated goat anti-rat Ab. Graphs are representative of two to five independent experiments. (C, 
lower row) bPMN (i), pPMN (ii), and TCF-PMN (iii) were immunolabeled with rabbit anti-CRAMP or 
isotype control (not shown) Ab followed by Cy3-conjugated donkey anti-rabbit Ab and examined by 
confocal microscopy. Isotype controls showed no detectable staining. Fluorescence micrographs 
(original magnification x100) are representatives of three independent experiments. 
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These results indicate that CRAMP-containing granules are not released during 
recruitment of PMN, such that full antimicrobial activity can be exerted at the site of 
infection. 
 
PMN release CRAMP after PKC activation 
Degranulation of secondary granules in human PMN was shown to be dependent on 
protein kinase C (PKC) (31). The signaling pathways promoting release of CRAMP 
after stimulation of murine PMN is unknown. We investigated the intrinsic ability of 
C57BL/6 pPMN to secrete CRAMP in response to the PKC activator PMA by flow 
cytometry. Unpurified pPMN were used to avoid preactivation of PMN by percoll 
purification. Therefore, two populations with bright and dim fluorescence are seen in 
the histograms, which were identified as PMN and monocytes by Wright’s stain (data 
not shown). As shown in Figure 2Cii, PMN correspond to the bright CRAMP-
expressing population. The fluorescence histogram of PMA-stimulated versus non-
treated cells shows a reduction in intracellular MFI. Intracellular CRAMP was 
significantly decreased after PMA-stimulation as shown in the bar graph indicating 
release of CRAMP. During secondary granule release lactoferrin and LL-37 
transiently locate to the cell surface (32, 33). Thus, we examined surface translocation 
of CRAMP as readout for secretion in response to PMA. Non-treated cells had no 
detectable CRAMP on their surface, whereas PMA-stimulated cells showed surface 
localization of CRAMP with significantly increased MFI compared to non-treated 
cells (Figure 3B). Using fluorescence microscopy we found that PMN stimulated for 
15 min with PMA had less intracellular CRAMP and its distribution was more 
disperse than in non-treated cells (Figure 3C). 
  49 
 
Figure 3. PMA-induced intracellular decrease and surface translocation of CRAMP. Flow 
cytometric analysis of unpurified pPMN from C57BL/6 mice stimulated for 15 min with PMA (black 
line) or left untreated (grey area) and subsequently stained with biotinylated rabbit anti-CRAMP or 
isotype control (grey line) Ab followed by RPE-conjugated Streptavidin. (A) Permeabilized cells 
stained for intracellular CRAMP and (B) non-permeabilized cells stained for surface-associated 
CRAMP. Bar graphs show MFI of non-treated (grey) and PMA-stimulated (black) pPMN. 
Representative histograms of two independent experiments are shown. Data are mean ± SD of two 
independent experiments with two mice per group. (C) Immunofluorescence of non-treated and PMA-
stimulated bPMN stained with rabbit anti-CRAMP Ab followed by Cy3-conjugated donkey anti-rabbit 
Ab. Fluorescence micrographs (original magnification x100) are representatives of three independent 
experiments. (D) Released CRAMP from bPMN non-stimulated or stimulated with PMA detected by 
ELISA. Significant differences are indicated by *: p<0.05 and ***: p<0.001. 
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Analysis of supernatants from PMA-stimulated PMN by ELISA confirmed that 
CRAMP was released after 30 min (Figure 3D). Other stimuli, such as fMLP, S. 
aureus lipoteichoic acid (LTA), the synthetic lipopeptide Pam3CSK4, or Salmonella 
abortus equis LPS, did not induce secretion of CRAMP (data not shown). These 
results give evidence that CRAMP is released from granules into the extracellular 
space after activation by PMA but not by a number of microbe-associated molecular 
patterns. 
 
CRAMP is recruited to the phagosome and kills S. aureus intracellularly 
The inability of PMN to secrete CRAMP after exposure to bacterial components 
raised the question whether viable S. aureus induce the release of CRAMP. In the 
following experiments we used the staphylococcal protein A (spa) deletion mutants 
SA113 ∆spa and ∆spa/∆dltA instead of SA113 wt and ∆dltA to avoid the confounding 
factor of unspecific IgG binding to Protein A. pPMN were infected with either SA113 
∆spa and ∆spa/∆dltA for 15 min and intracellular CRAMP expression and surface 
localization was studied by flow cytometry. In pPMN infected with either SA113 
∆spa and ∆spa/∆dltA intracellular and surface localization of CRAMP remained 
unaltered compared to non-treated cells (Figure 4A-B). 
Interestingly, confocal microscopy revealed that CRAMP localized with internalized 
S. aureus strains after infection (Figure 4C-D, arrows). We hypothesized that this 
localization of CRAMP is the result of granule fusion with S. aureus-containing 
phagosomes. Indeed, the phagosomal marker LAMP-1 colocalized with CRAMP at 
the site of S. aureus-containing phagosomes (Figure 4Civ,Div, arrows). 
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Figure 4. Intracellular localization and activity of CRAMP in S. aureus infection. Flow cytometric 
analysis of pPMN from C57BL/6 mice infected for 15 min with SA113 ∆spa (black line) and SA113 
∆spa/∆dltA (grey line) or left untreated (grey area) stained with biotinylated rabbit anti-CRAMP or 
isotype control (dotted line) Ab followed by RPE-conjugated Streptavidin. (A) Permeabilized cells 
stained for intracellular CRAMP and (B) non-permeabilized cells stained for surface-associated 
CRAMP. Bar graphs show MFI of non-treated (grey), SA113 ∆spa-infected (black), and SA113 
∆spa/∆dltA-infected (white) PMN. Representative histograms of three independent experiments are 
shown. Data are mean ± SD of three independent experiments with two mice per group. (C, D) 
Immunofluorescence of bPMN infected for 30 min with FITC-labeled SA113 ∆spa and ∆spa/∆dltA 
(MOI 1). Colocalization of CRAMP, FITC-labeled S. aureus, and LAMP-1: (i) immunostaining of 
CRAMP with biotinylated rabbit anti-CRAMP Ab followed by Streptavidin-Alexa647, (ii) FITC-
labeled SA113 ∆spa and ∆spa/∆dltA, (iii) immunostaining of LAMP-1 with rabbit anti-LAMP-1 Ab 
followed by Cy3-conjugated donkey anti-rabbit Ab, and (iv) overlay of i-iii. Arrows indicate 
colocalization of markers with S. aureus. Fluorescence micrographs (original magnification x150) are 
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representatives of three independent experiments. (E) Intracellular killing of SA113 wt (closed) and 
∆dltA (open) (MOI 1) by pPMN of C57BL/6 mice 30 min after infection. Data are mean ± SEM of 
three independent experiments. Significant differences are indicated by *: p<0.05. (F) Immunoblotting 
of PMN lysates. 1x106 pPMN of C57BL/6 mice were lysed, cell lysates were run on SDS-PAGE and 
analyzed by immunoblotting with rabbit anti-CRAMP or isotype control Abs. Lysates of untreated 
PMN (lane 1) and PMN infected with SA113 wt (lane 2). 10 µg of total protein of lysates were loaded 
per lane. Immunoblots with isotype control antibody was negative. 
Granule fusion to the phagosome was also confirmed by colocalization of CRAMP 
with cathepsin D (data not shown). No differences in localization of CRAMP toward 
the resistant SA113 ∆spa and the CRAMP-susceptible ∆spa/∆dltA mutant were 
observed. Secretion of CRAMP into the extracellular space after 30 min of infection 
with both strains was not detectable by ELISA (data not shown). Although PMN are 
able to secrete CRAMP after soluble stimuli, these data point toward a preferential 
intracellular retention of CRAMP in infection to kill S. aureus in phagolysosomes. 
Consequently, we performed an intracellular killing assay using S. aureus infected 
pPMN to evaluate whether CRAMP is not only recruited but also active in 
phagolysosomes. SA113 wt and ∆dltA were killed intracellularly to 41.2% and 
70.77%, respectively (Figure 4E). SA113 ∆dltA was significantly more susceptible to 
such intracellular killing. From this finding we conclude that the active form of 
CRAMP is present in phagolysosomes. 
To show whether CRAMP is processed from its precursor to its active form in the 
phagosomes, pPMN were stimulated with SA113 wt and analyzed by SDS-PAGE and 
Western blot. In both untreated and infected cells, the pro-form of CRAMP appeared 
as two bands at 18 kDa and a faint band of the cleaved 5 kDa form of CRAMP was 
found in uninfected cells and after phagocytosis of SA113 wt (Figure 4F) indicating 
intracellular processing of CRAMP. 
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CRAMP is present in NETs but DNA-binding reduces CRAMP activity 
Besides their phagocytic activity, human neutrophils were recently found to 
extracellularly entrap and kill S. aureus by forming NETs when phagocytic killing is 
exhausted (34). Proteases and antimicrobial peptides are associated with NETs 
comprising an extracellular site of bactericidal action of granule contents (35). 
Therefore, we first investigated NETs induction in murine PMN following stimulation 
with PMA or SA113 ∆spa. Following both stimuli, NET formation was induced 
within 4h in bPMN (Figure 5Aii,Bii) and pPMN (not shown); unstimulated cells did 
not release DNA (Figure 5Av). In PMA-induced NETs, CRAMP was associated with 
extracellular DNA (Figure 5Aiv). In NETs induced by S. aureus, CRAMP colocalized 
with entrapped bacteria (Figure 5Biv, arrow). These results raised the possibility that 
association within NETs represents an extracellular site of action for CRAMP. To 
investigate the antibacterial activity of NETs, PMA-activated pPMN were incubated 
with SA113 wt and ∆dltA in the presence of cytochalasin D to inhibit phagocytic 
uptake. Both, SA113 wt and ∆dltA were killed with similar efficiency in the presence 
of NETs (Figure 5C). Interestingly, when NETs were degraded with DNase, the 
killing of SA113 wt was completely abolished while ∆dltA remained partially 
susceptible. From the similar susceptibility of SA113 ∆dltA and wt to NET-dependent 
killing we conclude that CRAMP, although present, is not the only important effector 
in the antimicrobial activity of NETs against S. aureus. Tight association of the 
cationic AMP with anionic DNA may reduce access of the peptide to the microbial 
cell surface. 
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Figure 5. Induction of NETs and antimicrobial activity against S. aureus. (A, B) 
Immunofluorescence of bPMN activated for 4h with PMA (Ai-iv) and SA113 ∆spa (B). Colocalization 
of DNA, CRAMP, and S. aureus: (i) bright field, (ii) SYTOX® Green-labeled DNA and SA113 ∆spa, 
(iii) immunostaining of CRAMP with rabbit anti-CRAMP Ab followed by Cy3-conjugated donkey 
anti-rabbit Ab, and (iv) merge of i-iii. (v) Immunofluorescence of unstimulated bPMN indicating no 
NETs formation after 4h. Arrows indicate colocalization of markers with S. aureus. Fluorescence 
micrographs (original magnification x150) are representatives of three independent experiments. (C) 
NET-dependent killing of SA113 wt and ∆dltA (MOI 0.01). NETs were treated with (open) or without 
(closed) DNase before infection to distinguish the contribution of DNA and the other NETs-
components to the killing. Data are mean ± SEM of three independent experiments. Significant 
differences are indicated by *: p<0.05 and ***: p<0.001. 
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NADPH oxidase is a weak contributor to CRAMP expression and response 
Phagosomal alkalization following the NADPH oxidase activation was proposed to be 
essential for liberating granule enzymes in the phagosome (16). These granule 
enzymes are likely necessary for cleavage of CRAMP into is active form raising the 
question if NADPH oxidase-dependent liberation of granule enzymes might affect the 
processing and activity of CRAMP. We hence investigated function and phagosome 
translocation of CRAMP in gp91phox-/- mice lacking a functional NADPH oxidase. We 
assessed the bactericidal activity of gp91phox-/- TCF-PMN toward SA113 wt and ∆dltA 
in vitro. gp91phox-/- TCF-PMN were highly impaired in the killing of both strains 
compared to C57BL/6 TCF-PMN (Figure 6A compared to Figure 1). The persistent 
increased susceptibility of SA113 ∆dltA in gp91phox-/- TCF-PMN suggests that they 
still possess active CRAMP. 
To exclude a defect in granule release we stimulated gp91phox-/- pPMN with PMA for 
15 min and studied intracellular CRAMP expression and surface localization by flow 
cytometry. The MFI of non-treated gp91phox-/- pPMN was lower than in pPMN of 
C57BL/6 mice (Figure 6B versus 4A) indicating a reduced basal intracellular 
CRAMP level. However, intracellular CRAMP was significantly decreased after 
PMA stimulation as shown in the fluorescence histogram and bar graph in Figure 6B 
(left panels). PMA-stimulated cells showed more surface localization of CRAMP than 
non-treated cells with significantly increased MFI (Figure 6B, right panels). 
Regarding degranulation we found no defect in gp91phox-/- pPMN. Further we infected 
gp91phox-/- PMN with SA113 ∆spa and ∆spa/∆dltA strains and observed that CRAMP 
was still recruited to internalized bacteria but LAMP-1 was only partially (Figure 
6Civ,Div, arrows). 
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Figure 6. Contribution of NADPH oxidase to CRAMP function. (A) Bactericidal activity of TCF-
PMN from gp91phox-/- mice. The numbers of viable CFU of SA113 wt (closed) and SA113 ∆dltA (open) 
after 2h of incubation with TCF-PMN are expressed as percentage of the initial inoculum. (B) Flow 
cytometric analysis of pPMN from gp91phox-/- mice stimulated for 15 min with PMA (black line) or left 
untreated (grey area) and stained with biontinylated rabbit anti-CRAMP or isotype control (grey line) 
Ab followed by RPE-conjugated Streptavidin. (left) Permeabilized cells stained for intracellular 
CRAMP and (right) non-permeabilized cells stained for surface-associated CRAMP. Bar graphs show 
MFI of non-treated (grey) and PMA-stimulated (black) pPMN. Representative histograms of three 
independent experiments are shown. Data are mean ± SD of 3 independent experiments. (C, D) 
Immunofluorescence of bPMN of gp91phox-/- mice infected for 30 min with FITC-labeled SA113 ∆spa 
(C) and ∆spa/∆dltA (D) (MOI 1). Colocalization of CRAMP, FITC-labeled S. aureus, and LAMP-1: (i) 
immunostaining of CRAMP with biotinylated anti-CRAMP Ab followed by Streptavidin-Alexa647, 
(ii) FITC-labeled SA113 ∆spa and ∆spa/∆dltA, (iii) immunostaining of LAMP-1 with rabbit anti-
LAMP-1 Ab followed by Cy3-conjugated donkey anti-rabbit Ab, and (iv) merge of i-iii. Arrows 
indicate colocalization of markers with S. aureus. Fluorescence micrographs (original magnification 
x150) are representatives of two independent experiments. (E) Intracellular killing of SA113 wt 
(closed) and ∆dltA (open) (MOI 1) by pPMN of gp91phox-/- mice 30 min after infection. Data are mean 
± SEM of 3 independent experiments. Significant differences are indicated by *: p<0.05 and **: 
p<0.01. 
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Intracellular killing assays revealed that gp91phox-/- PMN are significantly impaired in 
intracellular clearance of SA113 wt (p=0.0109) and ∆dltA (p=0.0392) compared to 
C57BL/6 PMN. SA113 ∆dltA remained more susceptible than wt (Figure 6E) 
suggesting the existence of active CRAMP in these PMN. The formation of NETs 
was described to be dependent on NADPH oxidase (13). Indeed, PMN from gp91phox-
/- mice were unable to induce NETs (data not shown). Taken together, the NADPH 
oxidase is only a weak contributor to the antimicrobial function of CRAMP. 
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Discussion 
Since the original discovery of CRAMP in murine PMN (10), most studies have been 
performed on CRAMP expression and function in keratinocytes and other epithelial 
cells. In this study we provide evidence that PMN-derived CRAMP confers 
antimicrobial activity against the pre-eminent human pathogen S. aureus. 
Furthermore, we identified two different sites of action of CRAMP: Intracellularly in 
the phagolysosome and extracellularly associated in NETs, accentuated by DNA 
degradation. 
To study CRAMP function, we made use of the CRAMP-susceptible S. aureus 
mutant ∆dltA. We had previously shown the CAMP susceptible phenotype of this 
mutant in vitro and in a local murine infection model (28). In this study, we showed 
that the susceptibility of SA113 ∆dltA to murine PMN was selectively mediated by 
CRAMP by the use of CRAMP-/- PMN. Thus, the dealanylated teichoic acids render 
S. aureus predominantly susceptible to CRAMP in PMN. The heightened 
susceptibility of SA113 ∆dltA to other PMN-derived AMPs (e.g.lactoferrin, 
lysozyme) was found to be less pronounced than for CRAMP (36, 37). Additionally, 
major contributions to resistance to other PMN-derived AMPs are provided by other 
staphylococcal virulence mechanisms, i.e. resistance to lysozyme is associated with 
acetylation of peptidoglycan (23) while resistance against lactoferrin (38) and 
lipocalin (39) are governed by multiple iron uptake systems in S. aureus, which might 
be not affected in the ∆dltA phenotype. 
Our results show that TCF-PMN remain active with CRAMP against S. aureus 
despite its high resistance against AMPs in vitro. Similarly, whole blood PMN from 
C57BL/6, but not from CRAMP-/- mice, blocked the proliferation of Group A 
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Streptococcus, another major Gram-positive pathogen with several well-defined 
cathelicidin resistance mechanism against CRAMP (11, 40). 
Most studies on PMN activation and degranulation have been performed using PMN 
isolated from peripheral blood. However, PMN exert their function in vivo mainly 
after exudation from blood. Here we show that secondary granules wherein CRAMP 
is stored are not extensively released during PMN migration. This finding is in 
agreement with a study of granule mobilization during in vivo exudation of human 
PMN. The authors showed that control and exudate PMN have similar total content of 
lactoferrin and myeloperoxidase in secondary and primary granules, respectively (41). 
Nevertheless, our result for TCF-PMN contrasts with a previous study showing that 
TCF-PMN from guinea pigs have reduced myeloperoxidase and lysozyme content 
compared to peritoneal exudate PMN (42). The authors suggested that partial 
degranulation has occurred during contact with the implanted tissue cage. The 
retention of secondary and also primary granules, which harbor the most potent 
antimicrobial peptides including CRAMP, during extravasation may be crucial for 
retaining the antimicrobial activity of PMN for deployment at the site of infection. 
 We observed that secretion of CRAMP is induced after activation of PKC by PMA, 
but not by stimulation with fMLP, staphylococcal LTA, Pam3CSK4, Salmonella-LPS, 
or after phagocytosis of viable S. aureus. The mobilizable granules of PMN differ in 
availability for exocytosis and follow a strict hierarchy of exocytosis. Secretory 
vesicles have the highest propensity for release followed by gelatinase granules, 
secondary granules, and primary granules. This hierarchy could be the explanation 
why stimulation with fMLP did not lead to a significant release of CRAMP, but the 
more powerful agonist PMA induced secretion of CRAMP. Stie et al. showed that the 
human cathelicidin hCAP-18 accumulates at the PMN surface following stimulation 
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by 1 µM fMLP (33). In our hands, 1 µM fMLP did not lead to the surface 
translocation of CRAMP in pPMN, which might be due to different reactivity of 
human blood and murine peritoneal PMN. Nevertheless, surface-translocated 
CRAMP of strongly activated PMN might contribute to the killing and degradation of 
bacteria during their phagocytosis. The signaling pathways that link ligation of 
surface receptors or activation of PKC to degranulation of secondary granules include 
phospholipids, the MAP kinase p38, Ca2+ and the Src kinase Fgr, Rab GTPases and 
finally SNARE molecules (31). Their respective roles for CRAMP mobilization are 
subject of further investigation. 
In infection, CRAMP was recruited to the phagosome where it exerted antimicrobial 
activity on S. aureus. This finding is confirmed by the work of Sorenson et al. 
showing hCAP-18 in the lumen of phagosomes after internalization of Latex beads by 
human PMN (1). By the increased susceptibility of SA113 ∆dltA to intracellular 
killing we showed that CRAMP was intraphagosomally active indicating that 
cleavage might have been occurred. Cathepsin D, a protease found in primary 
granules, was recruited to the phagosome as well. In hand with primary granule 
release into the phagosome, other cathepsins and neutrophil elastase accumulate in the 
lumen and might cleave CRAMP to the active form. By immunoblotting, we showed 
that intracellular CRAMP was mainly present as pro-form as it was shown for the 
human hCAP18/LL-37 (1). However, low amounts of the active form were 
detectable. This unexpected finding was contradictory to our high intracellular killing 
of SA113 ∆dltA. Therefore, we think that active CRAMP might interact with 
negatively charged macromolecules (e.g.DNA) as shown for LL-37 (43, 44) or the 
bacterial membrane, which could explain low detectable amounts. 
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We demonstrated that murine PMN are able to form NETs after activation by PMA 
and viable S. aureus in a fashion similar to human PMN. In addition, CRAMP was 
localized in NETs and with entrapped S. aureus. CRAMP activity could not fully 
explain the NET-mediated killing of S. aureus, since SA113 wt and ∆dltA were killed 
to a similar extent. Extracellular killing of S. aureus therefore requires contributions 
from additional antimicrobial components of NETs, including histones. This is 
consistent with the finding that human NETs pretreated with antibodies against 
histones show reduced killing of S. aureus and Shigella flexneri (34). In contrast, D-
alanylation of teichoic acids enhances resistance against NET-dependent killing in 
non-encapsulated but not encapsulated S. pneumoniae (35). Unlike S. aureus and 
other pathogens, pneumococci are not killed by the antimicrobial components in 
NETs (45). Therefore, the authors argued that NET-dependent killing was a 
cooperative effect of enhanced trapping and increased autolysis of non-encapsulated 
∆dltA pneumococci. More importantly, we showed that the bactericidal activity of 
CRAMP is impaired when associated with NETs, while release of soluble CRAMP 
after degradation of the DNA backbone of NETs restored bactericidal activity of 
CRAMP against SA113 ∆dltA. Our study provides first evidence that NET-associated 
AMP may be in a state of reduced activity; this idea is supported by the fact that the 
antimicrobial activity of LL-37 is inactivated by binding to DNA (44). We 
hypothesize that NETs may serve as a storage site of antimicrobial active peptides and 
enzymes to combat bacteria that are freed during NET breakdown or following 
DNase expression by certain pathogens. 
We found reduced killing of S. aureus by PMN from gp91phox-/- mice and normal 
degranulation after PMA activation similar to human CGD PMN (22). The proposed 
dependence of granular proteases liberation on the NADPH oxidase (18) let us 
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hypothesize an impaired processing of CRAMP in gp91phox-/- mice. However, we 
could not find a link between the activity of the NADPH oxidase and CRAMP 
activity as SA113 ∆dltA remained significantly more susceptible to killing by 
gp91phox-/- PMN than the wt. The level of CRAMP was reduced in the absence of a 
functional NADPH oxidase. Both membrane subunits of the NADPH oxidase are 
absent in CGD patients with mutations in either the gp91phox or p22phox genes as well 
as in gp91phox-/- mice (46, 47). As CRAMP and the membrane subunits of NADPH 
oxidase are normally localized in the secondary granules (48), a lack of the NADPH 
oxidase membrane complex might alter membrane integrity and thereby leading to 
reduced granular content. Another explanation for the reduced intracellular CRAMP 
level might be augmented degranulation as previously described for primary granules 
in CGD neutrophils resulting in decreased levels of human -defensins HNP 1-3 (49). 
The results of our study provide first evidence that PMN-derived CRAMP exhibits 
direct intracellular activity ensuring rapid initial protection from invading pathogens. 
NETs harboring CRAMP during prolonged infection may serve for storing AMPs, 
which might be freed during DNase expression by certain pathogens. 
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Abstract 
We previously published that TLR2 contributes to efficient clearance of 
Staphylococcus aureus by polymorphonuclear leukocytes (PMN) in a local murine 
infection model. This study focused on the role of TLR2 in the activation of non-
oxidative and oxidative killing mechanisms against S. aureus. We show that TLR2 
clearly contributes to killing of S. aureus. The importance of antimicrobial peptide 
was shown in CRAMP-deficient PMN where killing of S. aureus was similarly 
reduced as in TLR2-deficient PMN. However, TLR2 was not involved in the 
regulation of CRAMP expression or function. PMN from gp91phox-/- were unable to 
eradicate S. aureus comparable to TLR2-/- PMN and suggested that TLR2 may act via 
the NADPH oxidase. Indeed, induction of oxidative burst was delayed in TLR2-
deficient PMN. We further investigated whether sensing of S. aureus by TLR2 is 
involved in the formation of neutrophil extracellular traps (NETs), which are induced 
when phagocytic killing is exhausted. Formation of NETs was independent of TLR2-
MyD88 signaling. Summarized, TLR2 enhances oxidative killing of S. aureus 
possibly by accelerating NADPH oxidase assembly in the phagosome. 
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Introduction 
Staphylococcus aureus (S. aureus) is a human commensal colonizing the skin and 
mucous membranes. When crossing the skin barrier, S. aureus causes abscess 
formation from which the bacteria can disseminate and cause severe systemic 
diseases. Once S. aureus breaches the skin barrier, polymorphonuclear leukocytes 
(PMN) are recruited to the site of infection to prevent further bacterial spread. Then, 
S. aureus is phagocytosed by PMN and eradicated by non-oxidative and oxidative 
mechanisms. The non-oxidative killing mechanisms are mediated by cationic 
antimicrobial peptides (CAMPs) such as defensins and cathelicidin stored in PMN 
granules. The oxidative mechanisms depend on reactive oxygen species (ROS) 
generated by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and 
myeloperoxidase (MPO). On one hand, the importance of non-oxidative killing comes 
clear in two rare inherited diseases, the Chediak-Higashi syndrome (1-3) and specific 
granule deficiency (4, 5). Both disorders are characterized by recurrent infections and 
shortened life expectancy underlining the fundamental role of granule proteins in host 
defense. On the other hand, the significance of ROS for antimicrobial activity is 
evidenced in patients with chronic granulomatous disease (CGD) lacking a functional 
NADPH oxidase complex and suffering from recurrent infections (6-9). All three 
diseases render patients susceptible to staphylococcal infection indicating that S. 
aureus has evolved the ability to resist both non-oxidative and oxidative PMN killing. 
Resistance to CAMPs is due to positive-charge modifications to the staphylococcal 
cell wall such as teichoic acid alanylation and peptidoglycan acetylation (10-12), 
whereas resistance to ROS is mediated by the expression of carotenoid pigment (13). 
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In addition to the intracellular killing mechanisms, PMN release neutrophil 
extracellular traps (NETs) consisting of chromosomal DNA and granule proteins (14). 
Formation of NETs presumably occurs after phagocytic killing mechanisms are 
exhausted. NETs then capture extracellular bacteria and are supposed to facilitate 
microbial killing by concentrating the antimicrobial arsenal to the site of infection and 
inhibiting further spreading. The formation of NETs was shown to be dependent on 
ROS and inhibitable by serum concentrations > 5% (15) but the precise mechanisms 
of NETs induction need further investigation. Traditionally, non-oxidative and 
oxidative killing mechanisms have been considered independent of each other. 
Recently, ROS have been implicated in the activation of granule proteases (16, 17). 
Activation of NADPH oxidase is followed by the influx of K+ and alkalization of the 
phagosome, which may be crucial to release the cationic granule proteases from the 
anionic proteoglycan matrix of the granules. 
Sensing of S. aureus is mediated by staphylococcal lipoproteins and to a lesser extent 
by lipoteichoic acids (LTA), which are recognized by Toll-like receptor (TLR) 2 and 
its comolecules CD14 and CD36 (18-22). After ligand binding, TLR2 forms 
heterodimers with either TLR1 or TLR6 (23); dimerization causes conformational 
changes thereby triggering activation of myeloid differentiation factor 88 (MyD88). 
TLR2-MyD88-signaling pathway results in the activation of NF-B and MAP kinases 
to induce pro-inflammatory genes and an antimicrobial response. The importance of 
TLR2 in inflammatory and antimicrobial response is evidenced in TLR2-deficient 
mice, which are highly susceptible to S. aureus septicemia (24), Streptococcus 
pneumoniae meningitis (25), and infections with Mycobacterium tuberculosis (26). 
We previously showed that TLR2 contributes to efficient clearance of S. aureus in a 
local infection model and that alanylation of LTA protected S. aureus from this 
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TLR2-mediated defense (27). The protective effect of LTA alanylation was 
tentatively correlated to the resistance against cationic antimicrobial peptides. 
Recently, we could demonstrate that the increased susceptibility of a S. aureus mutant 
deficient in the gene dltA for alanylation of teichoic acids, SA113 ∆dltA, to PMN-
dependent killing is predominantly mediated by the murine cathelicidin CRAMP (28). 
Therefore, we here investigate whether TLR2 regulates the antimicrobial defense 
against S. aureus by activating non-oxidative and oxidative killing mechanisms. 
We show that TLR2 on murine PMN enhances killing of S. aureus in vitro. However, 
TLR2 had no influence on expression level of the murine cathelicidin CRAMP and 
granule recruitment to phagosomes was TLR2-independent. Activation of TLR2 
signaling accelerated the generation of superoxide induced by S. aureus. In contrast, 
formation of NETs was independent of TLR2-MyD88 signaling. 
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Materials and Methods 
Bacterial strains. S. aureus wt (ATCC 35556, SA113 wt) and its isogenic mutants 
∆dltA, ∆spa, and ∆spa/∆dltA were grown overnight in tryptic soy broth (Difco) at 
37°C. For stimulation experiments, a subculture was inoculated 1:100 (v/v) from 
overnight culture in fresh tryptic soy broth and grown to late-log phase. Bacteria were 
washed twice with 0.9% NaCl prior to use. 
 
FITC-labeling of staphylococci. S. aureus subculture was grown to mid-log phase in 
fresh tryptic soy broth. Bacteria were washed twice with 0.9% NaCl and labeled in 
0.1 mg/ml FITC (Sigma) in PBS for 1h at 37°C with shaking. Prior to use, bacteria 
were washed twice with 0.9% NaCl and resuspended in Dulbecco’s PBS with 100 
mg/L MgCl2 and 100 mg/L CaCl2 (DPBS++, Invitrogen). 
 
Mice and tissue cage model. C57BL/6, TLR2-/-, CRAMP-/-, and gp91phox-/- mice were 
kept under specific pathogen-free conditions in the Animal House of the Department 
of Biomedicine, University Hospital Basel, and University of California, San Diego, 
according to the regulations of the Swiss veterinary law and the Veterans 
Administration of San Diego Committee on Animal Use, respectively. Mice were 
euthanized by CO2 or i.p. injection of 500 mg/kg Thiopenthal (Abbott 
Laboratories). 
12-14-weeks-old female mice were anesthetized and sterile Teflon tissue cages were 
implanted subcutaneously, as described previously (27). Two weeks after surgery, the 
sterility of tissue cages was verified. To harvest tissue cage fluid (TCF) for isolation 
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of PMN, mice were anesthetized by isofluorane (MINRAD INC.) and TCF 
percutaneously collected with EDTA. 
 
Antibody generation. Two New Zealand White rabbits were immunized by 
repetitive subcutaneous injections of 150 µg synthetic CRAMP (GL Shangai Biochem 
Ltd.) in adjuvant (MPL® + TDM + CWS Adjuvant System, Sigma) at monthly 
intervals. The titer of the antiserum was estimated by immunoblotting. The IgG 
fraction from the polyclonal anti-serum was isolated on a protein-G sepharose 
(Amersham) column and further affinity purified on CRAMP-coupled NHS-activated 
sepharose (GE Healthcare). Bound antibody was eluted with 0.1 M glycin (0.002% 
sodium azide, pH 2.5) and dialyzed against PBS. A portion of the antibody 
preparation was biotinylated as described previously (29), dialyzed against PBS and 
stored at -20°C. 
 
PMN isolation. For peripheral blood PMN (bPMN), mouse blood was harvested by 
intracardiac puncture in EDTA. bPMN were isolated as described previously for 
human PMN (30), but using a modified density gradient centrifugation on a 
discontinuous Percoll gradient with 59% and 67% Percoll (Amersham Biotech) in 
PBS. bPMN were collected at the interface of the two Percoll layers. 
For peritoneal PMN (pPMN), 1 ml of 3% thioglycollate (BD Biosciences) were 
injected i.p. After 6h, pPMN were collected by peritoneal lavage with 5 ml RPMI 
1640 complete medium (5% FBS, 2 mM glutamate, 1 mM sodium pyruvate, 1.5 mM 
HEPES, non-essential amino acids) and pelleted by centrifugation. 
For TCF-PMN, TCF was collected in EDTA and pelleted by centrifugation. 
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Stimulation of PMN for flow cytometry and immunofluorescence. After isolation 
from blood, peritoneum, or TCF, erythrocytes were lysed in water and PMN were 
resuspended in DPBS++ at 1-2x106 cells/ml. PMN were incubated with 1 µg/ml PMA, 
unlabeled (for flow cytometry) or FITC-labeled (for immunofluorescence) SA113 
∆spa and SA113 ∆spa/∆dltA for 15 and 30 min at 37°C, 200 rpm. Stimulation was 
stopped on ice and PMN were collected by centrifugation for further use in flow 
cytometry or immunofluorescence 
 
Immunofluorescence. After stimulation, cells were spun onto glass coverslips and 
fixed with 4% paraformaldehyde (PFA) in PBS for 30 min at room temperature (RT). 
After permeabilization with 0.2% saponin for 30 min at RT and 5 min in methanol, 
cells were blocked with 2% normal goat or donkey serum (NGS or NDS) for 30 min 
at RT. Cells were stained with affinity-purified polyclonal rabbit anti-CRAMP (1 
µg/ml), biotinylated rabbit anti-CRAMP (5 µg/ml), goat anti-cathepsin D (10 µg/ml, 
Santa Cruz Biotechnology), and rabbit anti-LAMP-1 (10 µg/ml, Abcam) Ab, 
followed by donkey anti-rabbit/goat IgG-Cy3 Ab (7.5 µg/ml, Jackson 
ImmunoResearch) or Streptavidin-Alexa647 (10 µg/ml, Molecular Probes). Isotype-
matched Ab served as negative controls. Specimens were analyzed with a Zeiss 
Axiovert 100M microscope (Carl Zeiss AG) using the confocal system LSM 510 
META and LSM 510 v3.2 SP2 software (Zeiss). 
 
Flow cytometry. Cells were blocked with 2% NGS, fixed with 4% PFA, and 
permeabilized for intracellular staining with 0.1% saponin. They were sequentially 
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stained with biotinylated rabbit anti-CRAMP Ab (1 µg/ml) and Streptavidin-RPE 
(0.25 µg/ml). Biotinylated rabbit IgG was used as isotype control. 
 
PMN killing assay. TCF-PMN were resuspended in DPBS++ (with 10% pooled 
mouse plasma) and 2x105 PMN were incubated with SA113 wt or ∆dltA at a 
multiplicity of infection (MOI) of 1h and incubated at 37°C, 200 rpm. After 2h, 
samples were diluted in H2O (pH 11) to lyse PMN and serial dilutions were plated on 
Mueller-Hinton agar (MHA) to enumerate surviving intra- and extracellular bacteria. 
 
Quantification of DNA release from activated neutrophils. TCF-PMN were 
resuspended in RPMI 1640 complete (2% FCS), seeded into 96-well plates 
(OptiPlate-96F, Perkin Elmer) at 2x105/well and stimulated with 50 nM PMA, SA113 
wt, and SA113 ∆dltA at MOI 10. After indicated time points, Sytox Green 
(MolecularProbes) was added to the cells at a final concentration of 10 μM to detect 
extracellular DNA. Non-stimulated TCF-PMN were used as control. The plates were 
read in a fluorescence microplate reader (Spectramax GeminiXS, Molecular Devices) 
with a filter setting of 485(excitation)/538 (emission). 
 
Superoxide production. Intracellular superoxide anion production of 2x105 TCF-
PMN was measured using luminol-enhanced chemiluminescence (31). TCF-PMN in 
DPBS++ were stimulated with 1 µg/mL PMA, SA113 wt, and SA113 ∆dltA at MOI 10 
in the presence of 50 µM luminol and 2000 Units catalase. Chemiluminescence was 
measured every 5 min throughout the stimulation with a luminometer (Microlumat 
Plus, Berthold Technologies). 
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Statistical analysis. PMN killing assay and in vivo experiments were analyzed with 
Mann-Whitney. Flow cytometry data, intracellular killing and NET-dependent killing 
assays were analyzed with paired student’s t-test. Generation of superoxide was 
analyzed with 2way-ANOVA. Statistical analysis was done with Prism 5.0a 
(GraphPad Software, Inc.). A p-value of p <0.05 was considered statistically 
significant. 
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Results 
TLR2-/- PMN have impaired bactericidal activity against S. aureus  
We previously showed that TLR2 contributes to efficient clearance of S. aureus in a 
local infection model and that alanylation of LTA protected S. aureus from this 
TLR2-mediated defense (27). The protective effect of LTA alanylation was 
tentatively correlated to the enhanced susceptibility of the ∆dltA mutant to CAMPs. 
Indeed, we could recently demonstrate that the increased susceptibility of SA113 
∆dltA to PMN-dependent killing is predominantly mediated by the murine 
cathelicidin CRAMP (28). Together, these results raised the hypothesis that TLR2 
might regulate the expression or function of CRAMP in murine PMN. 
 
 
Figure 1. Bactericidal activity of TCF-PMN and in vivo growth of S. aureus in CRAMP-/- mice. 
(A) The numbers of viable CFU of SA113 wt (closed) and SA113 ∆dltA (open) after 2h of incubation 
with TCF-PMN of C57BL/6 and TLR2-/- mice are expressed as percentage of the initial inoculum. (B) 
In vivo bacterial growth for 14 days after infection with 105 cfu of SA113 wt (closed) and ∆dltA (open) 
in CRAMP-/- mice. Data are mean ± SD of three independent experiments. Significant differences are 
indicated by *: p<0.05, **: p<0.01 and ***: p<0.001. 
We investigated whether TLR2 enhances killing of S. aureus by comparing the 
bactericidal activity of TLR2-/- and C57BL/6 PMN towards SA113 wt and ∆dltA. 
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Indeed, PMN isolated from tissue cage fluid (TCF-PMN) of TLR2-/- mice exhibited 
significantly decreased bactericidal activity against SA113 wt and ∆dltA compared to 
C57BL/6 TCF-PMN (Figure 1A) confirming the results found in vivo (27). SA113 wt 
and ∆dltA survived much better in the presence of TLR2-/- than C57BL/6 TCF-PMN, 
but the enhanced susceptibility of ∆dltA to killing persisted in TLR2-/- TCF-PMN, 
indicating the presence of active cathelicidin in TLR2-/- TCF-PMN. Interestingly, the 
percentage of surviving SA113 wt (213.0% ± 70.77) and ∆dltA (118.3% ± 62.46) in 
presence of TLR2-/- TCF-PMN was similar to the percentages of SA113 wt (214.9% ± 
53.5) and ∆dltA (177.4% ± 30.01) in the presence of CRAMP-/- TCF-PMN published 
earlier (28). Additionally, in vivo experiments revealed similar growth of SA113 wt 
and ∆dltA in CRAMP-/- mice (Figure 1B), which was comparable to the results 
previously found in TLR2-/- mice. These data give first evidence that TLR2 might 
mediate staphylococcal killing by regulating the expression or function of CRAMP in 
PMN. 
 
TLR2-deficient PMN have normal levels of CRAMP 
To investigate whether CRAMP expression is affected by TLR2-deficiency we 
compared intracellular CRAMP levels of TLR2-/- and C57BL/6 PMN by flow 
cytometry. Cells from murine peripheral blood, TCF, and peritoneal exudates were 
used to cover the different populations of PMN encountered by S. aureus in vivo. 
Intracellular expression of CRAMP shown as mean fluorescence intensity (MFI) was 
similar in PMN from TLR2-/- and C57BL/6 mice (Figure 2A). Additionally, MFI of 
PMN from different sites were comparable indicating minor degranulation of 
CRAMP during PMN exudation from blood. Immunofluorescence revealed that 
cellular distribution of CRAMP was similar in TCF-PMN of TLR2-/- and C57BL/6 
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mice (Figure 2B). In addition, the experiment identified PMN as the major CRAMP-
expressing cells in TCF, as monocytes showed no positive staining for CRAMP 
(arrows). These results indicate that TLR2-deficiency does not affect expression of 
CRAMP in PMN granules. 
 
 
Figure 2. Intracellular CRAMP expression in blood and exudate PMN. (A) MFI of purified blood 
PMN, peritoneal exudate cells, and TCF cells from C57BL/6 and TLR2-/- mice intracellularly stained 
with biotinylated rabbit anti-CRAMP Ab followed by RPE-conjugated Streptavidin and analyzed by 
flow cytometry. (B) Immunostaining of CRAMP in TCF cells examined by confocal microscopy. (i) 
Bright field, (ii) immunostaining of CRAMP with rabbit anti-CRAMP Ab followed by Cy3-conjugated 
donkey anti-rabbit Ab, and (iii) merge. Fluorescence micrographs (original magnification x64) are 
representatives of three independent experiments. Arrows indicate unstained monocytes. 
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Granule recruitment to S. aureus-containing phagosomes is TLR2-independent 
The reduced antimicrobial activity of TLR2-/- PMN against S. aureus could further 
base on a defect in degranulation or impaired recruitment of granules to phagocytosed 
S. aureus. In TLR2-deficient macrophages, a defect in phagosome maturation was 
described (32). We recently observed that release of cathelicidin of peritoneal PMN 
takes neither place after stimulation with staphylococcal LTA and synthetic 
lipopeptide nor after phagocytosis of S. aureus and can therefore rule out a defect in 
degranulation (28). To address recruitment of granules to phagosomes we used the 
staphylococcal protein A (spa) deletion mutants SA113 ∆spa and ∆spa/∆dltA instead 
of SA113 wt and ∆dltA to avoid the confounding factor of unspecific IgG binding to 
Protein A. pPMN were infected with FITC-labeled SA113 ∆spa and ∆spa/∆dltA for 
30 min and CRAMP was stained to localize secondary granules after infection. 
CRAMP colocalized with internalized S. aureus strains in TLR2-/- PMN similar as in 
C57BL/6 PMN (Figure 3); no differences in localization of CRAMP toward the 
resistant SA113 ∆spa and the CRAMP-susceptible ∆spa/∆dltA mutant were 
observable. Summarized, the normal expression level and recruitment of granules to 
phagosomes in PMN point toward a TLR2-mediated bactericidal mechanism 
independent of cathelicidin. 
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Figure 3. Intracellular localization of CRAMP in S. aureus infection. Immunofluorescence of 
bPMN of C57BL/6 and TLR2-/- mice infected for 30 min with FITC-labeled SA113 ∆spa and 
∆spa/∆dltA (MOI 10). Colocalization of CRAMP and FITC-labeled S. aureus: (i) immunostaining of 
CRAMP with rabbit anti-CRAMP Ab followed by Cy3-conjugated donkey anti-rabbit Ab, (ii) FITC-
labeled SA113 ∆spa and ∆spa/∆dltA, and (iii) overlay. Fluorescence micrographs (original 
magnification x100) are representatives of three independent experiments. 
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TLR2 signaling accelerates oxidative burst 
The findings so far excluded an involvement of TLR2 in non-oxidative killing 
mechanisms of PMN. A recent study showed that phosphorylation of the NADPH 
oxidase subunit p47phox is dependent on TLR2 and macrophages of TLR2-/- mice 
showed no superoxide and H2O2 production (33). Additionally, Laroux et al. showed 
that MyD88 controls assembly of the NADPH oxidase and killing of gram-negative 
bacteria (34). Based on these findings, the TLR2-mediated bactericidal activity 
against S. aureus might be attributed to oxidative killing mechanisms. We thus first 
determined the bactericidal activity of gp91phox-/- TCF-PMN against S. aureus. 
gp91phox-/- TCF-PMN were highly impaired in staphylococcal killing (Figure 4). This 
implies that the NADPH oxidase is involved in staphylococcal defense. 
 
Figure 4. Impact of TLR2 on oxidative burst in PMN. (A) The numbers of viable CFU of SA113 wt 
(closed) and SA113 ∆dltA (open) after 2h of incubation with TCF-PMN from gp91phox-/- mice are 
expressed as percentage of the initial inoculum. (B) S. aureus-induced production of intracellular 
superoxide in TCF-PMN from C57BL/6, TLR2-/-, and gp91phox-/- mice measured by luminol-enhanced 
chemiluminescence. Data are mean ± SD of two independent experiments. Significant differences are 
indicated by *: p<0.05, **: p<0.01, and ***: p<0.001. 
The involvement of TLR2 in the signaling process leading to activation of NADPH 
oxidase and generation of ROS was tested in PMN of TLR2-/- and C57BL/6 mice. 
PMA served as control stimulus and induced a rapid production of superoxide 
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measured by luminol-enhanced chemiluminescence (Figure 4B). Interestingly, 
production of superoxide induced by S. aureus was delayed in TLR2-/- compared to 
C57BL/6 PMN. This result indicates acceleration of oxidative burst by TLR2 
signaling. Further investigation will reveal if a delay in assembly of the NADPH 
oxidase or reduced phosphorylation of subunits causes this defect in TLR2-/- PMN. 
 
Induction of NETs is independent of TLR2-MyD88 signaling 
NETs are made by neutrophils activated with an increasing number of stimuli. 
However, not much is known about exact induction pathways. Urban et al. assumed 
that Fc receptors or pattern-recognition receptors such as TLRs might be involved 
(35). The formation of NETs is dependent on the activation of the NADPH oxidase 
(15). With the observed delay of oxidative burst in TLR2-/- PMN formation of NETs 
might be affected as well. Thus, we analyzed whether TLR2 and MyD88 are involved 
in the induction of NETs by S. aureus. One to 3 hours post-infection with S. aureus, 
PMN from TLR2-/- and MyD88-/- mice released NETs comparable to C57BL/6 mice 
(Figure 5). Control PMN from gp91phox-/- mice were unable to produce NETs. Taken 
together, these data show that TLR2-MyD88 signaling is not involved in NET 
formation indicating that phagocytic or complement receptors might be of importance 
in this process. 
 
 92
 
Figure 5. Role of TLR2 signaling in formation of NETs. Quantification of NETs formation by TCF-
PMN of C57BL/6, TLR2-/-,MyD88-/-, and gp91phox-/- mice activated for 1 hour (A) and 3 hours (B) with 
PMA (stripped), SA113 wt (filled), and ∆dltA (open). Untreated PMN (grey) were used as negative 
control. 
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Discussion 
The role of TLRs in the regulation of antimicrobial peptide expression was first 
described in Drosophila. Expression of human beta-defensin hBD-2 was induced by 
activation of TLR2 by bacterial lipoprotein in lung epithelial cells (36). TLR2 
activation by soluble agonists enhanced cathelicidin protein expression in human 
macrophages (37) and CRAMP mRNA in murine fibroblasts (38). Recently, 
staphylococcal lipoproteins were evidenced to up-regulate human cathelicidin and 
hBD-2 in a TLR2-dependent manner in corneal epithelial cells (39). Altogether 
previous studies supported the hypothesis of a possible interaction between TLR2 and 
CAMP-mediated host defense. 
We confirmed the importance of TLR2 in efficient killing of S. aureus by PMN. In 
line with our previous findings in vivo, alanylation of teichoic acid protected S. aureus 
from killing. Additionally, S. aureus infection in CRAMP-deficient mice mirrored the 
situation published for TLR2-deficient mice where S. aureus wt and ∆dltA showed 
similar growth strengthening our hypothesis. However, our study revealed a 
negligible role of TLR2 in the expression of CRAMP as well as in secondary granule 
recruitment to phagosomes in PMN. PMN, which have a life span of only a few 
hours, do store cathelicidin in the secondary granules as inactive form and processing 
after activation of the cell confers rapid antimicrobial defense. Since PMN are the 
first cells recruited to the site of infection we consider that they use their antimicrobial 
arsenal to eradicate bacteria after phagocytosis independently of TLR2. In epithelial 
cells and macrophages, cathelicidin is constitutively not or only weakly expressed and 
its expression is up-regulated after infection. Therefore, sensing pathogens by TLR2 
and resulting up-regulation of cathelicidin in long-lived epithelial cells and 
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macrophages seems necessary to provide subsequent protection after the first 
intervention of PMN. 
Nevertheless, TLR2 contributed to oxidative killing by accelerating NADPH oxidase 
activation. In agreement with this, we have previously shown that TLR2 enhanced 
oxidative killing of pneumoccoci in murine PMN (40). Additionally, p47phox mRNA 
induction and phosphorylation were found TLR2-dependent in infected macrophages 
(33, 41). The role of TLRs in oxidative burst generation is further documented as 
mice, which lack MyD88, a downstream adaptor of TLR2, failed to produce reactive 
oxygen upon stimulation with group B streptococci (42). Furthermore, MyD88 
enhanced NADPH oxidase assembly and controlled killing of gram-negative bacteria 
(34). Future investigation will reveal the molecular mechanism of TLR2-mediated 
oxidative killing and in particular whether TLR2 activation affects translocation and 
assembly of the NADPH oxidase. 
PMN are able to form NETs that trap and degrade bacteria. The presence of bacteria 
activates PMN and leads to the formation of NETs. Urban et al. proposed that Fc 
receptors and pattern-recognition receptors might be involved in the initiation of 
NETs formation by opsonized and non-opsonized microbes (35). Here, we showed 
that induction of NETs formation by non-opsonized S. aureus is independent of 
TLR2-MyD88-signaling. It is now known that induction of NETs depends on ROS-
signaling, as inhibition of H2O2 formation blocked NET formation and application of 
H2O2 to PMN from CGD patients led to formation of NETs (15). Additionally, NET 
formation is inhibited in a concentration-dependent fashion by serum due to its 
antioxidant activity (15, 43). On the other hand, ROS production can be induced by 
stimulation of PMN with specific TLR ligands. LPS-induced TLR4-MyD88-IRAK-4 
signaling was shown to regulate NADPH oxidase activation (44-47). However, only a 
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few reports have clearly identified the interplay between TLRs and NADPH oxidases 
and needs further investigation. Therefore, signaling mechanisms involved in NETs 
formation by different stimuli might be complicated but future studies on ROS and 
TLR signaling will help to fully understand the process of NET formation. 
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5. Overall Discussion 
In the first part of this thesis we aimed to investigate the antimicrobial potential of 
neutrophil-derived CRAMP in staphylococcal killing. The focus was on the 
identification of its site of action, since little is known so far about extra- or 
intracellular activity of neutrophil-derived cathelicidins. Although the human 
cathelicidin hCAP-18 is secreted to the extracellular space by neutrophils after soluble 
stimuli (14), it is plausible that a particle stimulus such as live S. aureus leads to 
release of cathelicidin into the phagolysosome. Evidence for this assumption is given 
by the fact that hCAP-18 is found in latex bead-containing phagosomes. Interestingly, 
cleavage of hCAP-18 was only observed extracellularly but not yet in the 
phagolysosome (14). Therefore, we intended to investigate extra- and intracellular 
activity of CRAMP against S. aureus and the presence of active CRAMP in 
phagolysosomes. 
We found that neutrophils retain CRAMP during the process of extravasation. This 
documents the importance of CRAMP to exert full antimicrobial activity at the site of 
infection. Although we found degranulation of CRAMP after strong activation of 
neutrophils, soluble MAMPs and importantly live S. aureus did not induce secretion 
of CRAMP to the extracellular space. In contrast, CRAMP was recruited to S. aureus-
containing phagolysosomes. Most interestingly, by using the CRAMP-susceptible 
S. aureus ∆dltA mutant we could demonstrate intracellular activity of CRAMP that 
was not reported before. The main function of CRAMP, therefore, seems to be 
intracellular. This finding is novel and contrasts with the known mainly extracellular 
activity of human cathelicidin. 
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A further approach in this study was to target the interaction of non-oxidative and 
oxidative killing mechanisms of neutrophils. 
A novel link between non-oxidative and oxidative mechanisms was found in the 
formation of NETs, which is dependent on ROS (72). Antimicrobial activity of NETs 
against several pathogens including S. aureus has been established but was not 
correlated to the AMP content. Since AMP activity in NET-association has not yet 
been addressed and might be of importance, we focused on the activity of CRAMP in 
NET-mediated defense. We demonstrated that CRAMP is in a state of reduced 
activity when associated with NETs and does not contribute to staphylococcal killing. 
This new finding contradicts the current opinion that NETs kill bacteria with locally 
concentrated AMPs. Whether this inactivation is common to all NET-associated 
AMPs remains unclear. Approaches addressing this question will be necessary for our 
detailed understanding how NETs exert microbial killing. We hypothesize that NETs 
serve as a storage site of antimicrobial active peptides and enzymes to combat 
bacteria that are freed during NET breakdown or following DNase secretion by 
certain pathogens including S. aureus. 
The ingenious model of synergistic interaction between the NADPH oxidase and 
granule-associated proteases proposed by Segal and co-workers did not consider that 
the subsequent activation of antimicrobial peptides might be affected as well (13). 
Therefore, we further addressed the relationship between a functional NADPH 
oxidase and the efficiency of CRAMP-mediated staphylococcal defense. Using 
gp91phox-/- mice, lacking a functional NADPH oxidase, we found normal CRAMP 
recruitment to the phagolysosome; however, intracellular CRAMP level and killing of 
S. aureus were reduced. Since intracellular killing of S. aureus ∆dltA remained 
enhanced, activation of CRAMP by granule proteases could not be correlated to the 
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NADPH oxidase in this study. While total killing of S. aureus by gp91phox-/- PMN was 
markedly reduced, intracellular killing was only slightly impaired. This might reflect 
an importance of ROS for extracellular but negligibility for intracellular killing. An 
additional finding during our observations was that LAMP-1, which we used as 
phagosomal marker, did only partially co-localize with S. aureus-containing 
phagosomes in gp91phox-/- neutrophils. Few studies are available localizing LAMP-1 in 
the neutrophil; however, LAMP-1 was identified in the membrane of multivesicular 
bodies (MVB) and multilaminar compartments (MLC) (103, 104). Little is known 
about the role of MVB and MLC in neutrophil phagosome formation but they are 
speculated to be the true lysosomes in neutrophils (105). Characterization of 
neutrophil MVB and MLC might broaden our knowledge of phagosome maturation in 
neutrophils and identify a possible role of the NADPH oxidase in this process. 
 
In the second part of this thesis we intended to investigate whether TLR2 mediates the  
activation of non-oxidative or oxidative killing mechanisms in response to S. aureus. 
TLR2 activation has been shown to up-regulate cathelicidin protein and mRNA 
expression in fibroblasts and epithelial cells (88, 89). Evidence for TLR2 in mediating 
a cathelicidin-dependent defense in neutrophils was proposed by our group before 
(96). First, we investigated the role of TLR2 in cathelicidin-mediated staphylococcal 
killing and the potential regulation of CRAMP. We showed that TLR2 contributes to 
efficient staphylococcal killing in neutrophils. A correlation of TLR2-mediated killing 
and CRAMP expression or phagosome recruitment was not found. In accordance with 
the neutrophil’s role in rapid defense these results underscore the concept of storing 
large amounts of inactive cathelicidin for immediate antimicrobial activity upon 
neutrophil activation. In contrast, cathelicidin expression is low in epithelial cells but 
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strongly up-regulated in infection. Accordingly, sensing pathogens by TLR2 and 
resulting up-regulation of cathelicidin is necessary to provide long-term protection by 
epithelial cells whereas the antimicrobial arsenal stored in neutrophil granules is 
sufficient for the first intervention by neutrophils. 
Since TLR2 clearly contributed to efficient staphylococcal killing in neutrophils, 
independent of CRAMP, we assumed that TLR2 might promote oxidative killing in 
response to S. aureus. Our hypothesis was supported by the fact that TLR2 enhances 
oxidative killing of pneumococci in murine PMN (106). In addition, a recent study 
showed that TLR2 activation induced the phosphorylation of the NADPH oxidase 
subunit p47phox in macrophages (107). 
Our results revealed that TLR2 activation by S. aureus accelerates the induction of an 
oxidative burst in neutrophils. Future experiments addressing the phosphorylation and 
kinetics of assembly of NADPH oxidase subunits will specify the position of TLR2 in 
promoting oxidative killing. Under assumption of Segal’s theory it may be argued that 
a delayed production of toxic ROS might additionally affect bacterial killing by 
hindering protease liberation and AMP activation. From this perspective, detailed 
examination of the relationship between TLR2 and NADPH oxidase activation will 
reveal further insights in the complex network of microbial sensing and killing. 
Recent work suggested that TLRs might be involved in the initiation of signaling 
cascades leading to the formation of NETs (108). Although proposed, this hypothesis 
has not been subject of recent studies and there is no clear evidence for it. Therefore, 
we investigated the induction of NETs under the focus of TLR2 signaling. Our results 
revealed that TLR2-MyD88 signaling is not involved in the induction of NETs by 
non-opsonized S. aureus. This result suggests that induction of NETs might rather 
depend on phagocytosis-mediated signaling events than pattern recognition receptors. 
 105
Clearly, future research is necessary to elucidate which signaling pathways lead to the 
induction of NETs and whether opsonization might be of influence. 
 
In conclusion, the direct interplay of non-oxidative and oxidative killing in 
neutrophils remains complicated and elusive. Overall, we believe that the neutrophil’s 
ability to target many essential processes of microbial pathogens and to synergize 
non-oxidative and oxidative mechanisms with one another results in broad 
antimicrobial activity that is difficult for microorganisms to completely resist or 
circumvent. This needs temporal and spatial coordination of the distinct defense 
mechanisms, which makes it difficult to separate these processes. The remaining 
uncertainties and controversies leave many fascinating questions in the interactions 
between neutrophils and microorganisms to answer. Nevertheless, a deeper 
understanding of this area would be of crucial importance in developing methods to 
interfere with both old and newly emerging pathogens. 

 107
6. References 
1. Bainton, D. F., and M. G. Farquhar. 1966. Origin of granules in 
polymorphonuclear leukocytes. Two types derived from opposite faces of the 
Golgi complex in developing granulocytes. J Cell Biol 28:277-301. 
2. Bainton, D. F., J. L. Ullyot, and M. G. Farquhar. 1971. The development of 
neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp 
Med 134:907-934. 
3. Agner, K. 1941. Verdoperoxidase. A ferment isolated from leucocytes. Acta 
Chem. Scand. 2:1-62. 
4. Klebanoff, S. J. 1999. Myeloperoxidase. Proc Assoc Am Physicians 111:383-
389. 
5. Ganz, T., M. E. Selsted, D. Szklarek, S. S. Harwig, K. Daher, D. F. Bainton, 
and R. I. Lehrer. 1985. Defensins. Natural peptide antibiotics of human 
neutrophils. J Clin Invest 76:1427-1435. 
6. Daher, K. A., M. E. Selsted, and R. I. Lehrer. 1986. Direct inactivation of 
viruses by human granulocyte defensins. J Virol 60:1068-1074. 
7. Lehrer, R. I., T. Ganz, D. Szklarek, and M. E. Selsted. 1988. Modulation of 
the in vitro candidacidal activity of human neutrophil defensins by target cell 
metabolism and divalent cations. J Clin Invest 81:1829-1835. 
8. Wimley, W. C., M. E. Selsted, and S. H. White. 1994. Interactions between 
human defensins and lipid bilayers: evidence for formation of multimeric 
pores. Protein Sci 3:1362-1373. 
9. Eisenhauer, P. B., and R. I. Lehrer. 1992. Mouse neutrophils lack defensins. 
Infect Immun 60:3446-3447. 
10. Campanelli, D., M. Melchior, Y. Fu, M. Nakata, H. Shuman, C. Nathan, and J. 
E. Gabay. 1990. Cloning of cDNA for proteinase 3: a serine protease, 
antibiotic, and autoantigen from human neutrophils. J Exp Med 172:1709-
1715. 
11. Salvesen, G., D. Farley, J. Shuman, A. Przybyla, C. Reilly, and J. Travis. 
1987. Molecular cloning of human cathepsin G: structural similarity to mast 
cell and cytotoxic T lymphocyte proteinases. Biochemistry 26:2289-2293. 
12. Sinha, S., W. Watorek, S. Karr, J. Giles, W. Bode, and J. Travis. 1987. 
Primary structure of human neutrophil elastase. Proc Natl Acad Sci U S A 
84:2228-2232. 
13. Reeves, E. P., H. Lu, H. L. Jacobs, C. G. Messina, S. Bolsover, G. Gabella, E. 
O. Potma, A. Warley, J. Roes, and A. W. Segal. 2002. Killing activity of 
neutrophils is mediated through activation of proteases by K+ flux. Nature 
416:291-297. 
14. Sorensen, O. E., P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. 
Hiemstra, and N. Borregaard. 2001. Human cathelicidin, hCAP-18, is 
processed to the antimicrobial peptide LL-37 by extracellular cleavage with 
proteinase 3. Blood 97:3951-3959. 
15. Cramer, E., K. B. Pryzwansky, J. L. Villeval, U. Testa, and J. Breton-Gorius. 
1985. Ultrastructural localization of lactoferrin and myeloperoxidase in human 
neutrophils by immunogold. Blood 65:423-432. 
16. Masson, P. L., J. F. Heremans, and E. Schonne. 1969. Lactoferrin, an iron-
binding protein in neutrophilic leukocytes. J Exp Med 130:643-658. 
 108
17. Oram, J. D., and B. Reiter. 1968. Inhibition of bacteria by lactoferrin and other 
iron-chelating agents. Biochim Biophys Acta 170:351-365. 
18. Kjeldsen, L., D. F. Bainton, H. Sengelov, and N. Borregaard. 1994. 
Identification of neutrophil gelatinase-associated lipocalin as a novel matrix 
protein of specific granules in human neutrophils. Blood 83:799-807. 
19. Kjeldsen, L., A. H. Johnsen, H. Sengelov, and N. Borregaard. 1993. Isolation 
and primary structure of NGAL, a novel protein associated with human 
neutrophil gelatinase. J Biol Chem 268:10425-10432. 
20. Triebel, S., J. Blaser, H. Reinke, and H. Tschesche. 1992. A 25 kDa alpha 2-
microglobulin-related protein is a component of the 125 kDa form of human 
gelatinase. FEBS Lett 314:386-388. 
21. Goetz, D. H., M. A. Holmes, N. Borregaard, M. E. Bluhm, K. N. Raymond, 
and R. K. Strong. 2002. The neutrophil lipocalin NGAL is a bacteriostatic 
agent that interferes with siderophore-mediated iron acquisition. Mol Cell 
10:1033-1043. 
22. Agerberth, B., H. Gunne, J. Odeberg, P. Kogner, H. G. Boman, and G. H. 
Gudmundsson. 1995. FALL-39, a putative human peptide antibiotic, is 
cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S 
A 92:195-199. 
23. Cowland, J. B., A. H. Johnsen, and N. Borregaard. 1995. hCAP-18, a 
cathelin/pro-bactenecin-like protein of human neutrophil specific granules. 
FEBS Lett 368:173-176. 
24. Gallo, R. L., K. J. Kim, M. Bernfield, C. A. Kozak, M. Zanetti, L. Merluzzi, 
and R. Gennaro. 1997. Identification of CRAMP, a cathelin-related 
antimicrobial peptide expressed in the embryonic and adult mouse. J Biol 
Chem 272:13088-13093. 
25. Larrick, J. W., M. Hirata, J. Zhong, and S. C. Wright. 1995. Anti-microbial 
activity of human CAP18 peptides. Immunotechnology 1:65-72. 
26. Borregaard, N., J. M. Heiple, E. R. Simons, and R. A. Clark. 1983. Subcellular 
localization of the b-cytochrome component of the human neutrophil 
microbicidal oxidase: translocation during activation. J Cell Biol 97:52-61. 
27. Jesaitis, A. J., E. S. Buescher, D. Harrison, M. T. Quinn, C. A. Parkos, S. 
Livesey, and J. Linner. 1990. Ultrastructural localization of cytochrome b in 
the membranes of resting and phagocytosing human granulocytes. J Clin 
Invest 85:821-835. 
28. Kang, T., J. Yi, A. Guo, X. Wang, C. M. Overall, W. Jiang, R. Elde, N. 
Borregaard, and D. Pei. 2001. Subcellular distribution and cytokine- and 
chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in 
neutrophils. J Biol Chem 276:21960-21968. 
29. Kjeldsen, L., O. W. Bjerrum, J. Askaa, and N. Borregaard. 1992. Subcellular 
localization and release of human neutrophil gelatinase, confirming the 
existence of separate gelatinase-containing granules. Biochem J 287 ( Pt 
2):603-610. 
30. Lazarus, G. S., R. S. Brown, J. R. Daniels, and H. M. Fullmer. 1968. Human 
Granulocyte Collagenase. Science 159:1483-1485. 
31. Murphy, G., J. J. Reynolds, U. Bretz, and M. Baggiolini. 1977. Collagenase is 
a component of the specific granules of human neutrophil leucocytes. Biochem 
J 162:195-197. 
 109
32. Pei, D. 1999. Leukolysin/MMP25/MT6-MMP: a novel matrix 
metalloproteinase specifically expressed in the leukocyte lineage. Cell Res 
9:291-303. 
33. Borregaard, N., and J. B. Cowland. 1997. Granules of the human neutrophilic 
polymorphonuclear leukocyte. Blood 89:3503-3521. 
34. Owen, C. A., and E. J. Campbell. 1999. The cell biology of leukocyte-
mediated proteolysis. J Leukoc Biol 65:137-150. 
35. Detmers, P. A., D. Zhou, D. Powell, H. Lichenstein, M. Kelley, and R. 
Pironkova. 1995. Endotoxin receptors (CD14) are found with CD16 (Fc 
gamma RIII) in an intracellular compartment of neutrophils that contains 
alkaline phosphatase. J Immunol 155:2085-2095. 
36. Sengelov, H., F. Boulay, L. Kjeldsen, and N. Borregaard. 1994. Subcellular 
localization and translocation of the receptor for N-formylmethionyl-leucyl-
phenylalanine in human neutrophils. Biochem J 299 ( Pt 2):473-479. 
37. Sengelov, H., L. Kjeldsen, M. S. Diamond, T. A. Springer, and N. Borregaard. 
1993. Subcellular localization and dynamics of Mac-1 (alpha m beta 2) in 
human neutrophils. J Clin Invest 92:1467-1476. 
38. Sengelov, H., L. Kjeldsen, W. Kroeze, M. Berger, and N. Borregaard. 1994. 
Secretory vesicles are the intracellular reservoir of complement receptor 1 in 
human neutrophils. J Immunol 153:804-810. 
39. Zanetti, M., R. Gennaro, and D. Romeo. 1995. Cathelicidins: a novel protein 
family with a common proregion and a variable C-terminal antimicrobial 
domain. FEBS Lett 374:1-5. 
40. Sorensen, O., K. Arnljots, J. B. Cowland, D. F. Bainton, and N. Borregaard. 
1997. The human antibacterial cathelicidin, hCAP-18, is synthesized in 
myelocytes and metamyelocytes and localized to specific granules in 
neutrophils. Blood 90:2796-2803. 
41. Johansson, J., G. H. Gudmundsson, M. E. Rottenberg, K. D. Berndt, and B. 
Agerberth. 1998. Conformation-dependent antibacterial activity of the 
naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724. 
42. Wang, G. 2008. Structures of human host defense cathelicidin LL-37 and its 
smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem 
283:32637-32643. 
43. Gutsmann, T., S. O. Hagge, J. W. Larrick, U. Seydel, and A. Wiese. 2001. 
Interaction of CAP18-derived peptides with membranes made from 
endotoxins or phospholipids. Biophys J 80:2935-2945. 
44. Oren, Z., J. C. Lerman, G. H. Gudmundsson, B. Agerberth, and Y. Shai. 1999. 
Structure and organization of the human antimicrobial peptide LL-37 in 
phospholipid membranes: relevance to the molecular basis for its non-cell-
selective activity. Biochem J 341 ( Pt 3):501-513. 
45. Agerberth, B., J. Charo, J. Werr, B. Olsson, F. Idali, L. Lindbom, R. Kiessling, 
H. Jornvall, H. Wigzell, and G. H. Gudmundsson. 2000. The human 
antimicrobial and chemotactic peptides LL-37 and alpha-defensins are 
expressed by specific lymphocyte and monocyte populations. Blood 96:3086-
3093. 
46. Di Nardo, A., A. Vitiello, and R. L. Gallo. 2003. Cutting edge: mast cell 
antimicrobial activity is mediated by expression of cathelicidin antimicrobial 
peptide. J Immunol 170:2274-2278. 
47. Dorschner, R. A., V. K. Pestonjamasp, S. Tamakuwala, T. Ohtake, J. Rudisill, 
V. Nizet, B. Agerberth, G. H. Gudmundsson, and R. L. Gallo. 2001. 
 110
Cutaneous injury induces the release of cathelicidin anti-microbial peptides 
active against group A Streptococcus. J Invest Dermatol 117:91-97. 
48. Frohm, M., B. Agerberth, G. Ahangari, M. Stahle-Backdahl, S. Liden, H. 
Wigzell, and G. H. Gudmundsson. 1997. The expression of the gene coding 
for the antibacterial peptide LL-37 is induced in human keratinocytes during 
inflammatory disorders. J Biol Chem 272:15258-15263. 
49. Rosenberger, C. M., R. L. Gallo, and B. B. Finlay. 2004. Interplay between 
antibacterial effectors: a macrophage antimicrobial peptide impairs 
intracellular Salmonella replication. Proc Natl Acad Sci U S A 101:2422-2427. 
50. Nizet, V., T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R. A. Dorschner, V. 
Pestonjamasp, J. Piraino, K. Huttner, and R. L. Gallo. 2001. Innate 
antimicrobial peptide protects the skin from invasive bacterial infection. 
Nature 414:454-457. 
51. Chromek, M., Z. Slamova, P. Bergman, L. Kovacs, L. Podracka, I. Ehren, T. 
Hokfelt, G. H. Gudmundsson, R. L. Gallo, B. Agerberth, and A. Brauner. 
2006. The antimicrobial peptide cathelicidin protects the urinary tract against 
invasive bacterial infection. Nat Med 12:636-641. 
52. Bergman, P., L. Johansson, H. Wan, A. Jones, R. L. Gallo, G. H. 
Gudmundsson, T. Hokfelt, A. B. Jonsson, and B. Agerberth. 2006. Induction 
of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges 
after meningococcal infection. Infect Immun 74:6982-6991. 
53. Clark, R. A., B. D. Volpp, K. G. Leidal, and W. M. Nauseef. 1990. Two 
cytosolic components of the human neutrophil respiratory burst oxidase 
translocate to the plasma membrane during cell activation. J Clin Invest 
85:714-721. 
54. Iyer, S. S., D. W. Pearson, W. M. Nauseef, and R. A. Clark. 1994. Evidence 
for a readily dissociable complex of p47phox and p67phox in cytosol of 
unstimulated human neutrophils. J Biol Chem 269:22405-22411. 
55. Park, J. W., M. Ma, J. M. Ruedi, R. M. Smith, and B. M. Babior. 1992. The 
cytosolic components of the respiratory burst oxidase exist as a M(r) 
approximately 240,000 complex that acquires a membrane-binding site during 
activation of the oxidase in a cell-free system. J Biol Chem 267:17327-17332. 
56. Abo, A., M. R. Webb, A. Grogan, and A. W. Segal. 1994. Activation of 
NADPH oxidase involves the dissociation of p21rac from its inhibitory 
GDP/GTP exchange protein (rhoGDI) followed by its translocation to the 
plasma membrane. Biochem J 298 Pt 3:585-591. 
57. Heyworth, P. G., B. P. Bohl, G. M. Bokoch, and J. T. Curnutte. 1994. Rac 
translocates independently of the neutrophil NADPH oxidase components 
p47phox and p67phox. Evidence for its interaction with flavocytochrome 
b558. J Biol Chem 269:30749-30752. 
58. Quinn, M. T., T. Evans, L. R. Loetterle, A. J. Jesaitis, and G. M. Bokoch. 
1993. Translocation of Rac correlates with NADPH oxidase activation. 
Evidence for equimolar translocation of oxidase components. J Biol Chem 
268:20983-20987. 
59. Cheng, N., R. He, J. Tian, M. C. Dinauer, and R. D. Ye. 2007. A critical role 
of protein kinase C delta activation loop phosphorylation in formyl-methionyl-
leucyl-phenylalanine-induced phosphorylation of p47(phox) and rapid 
activation of nicotinamide adenine dinucleotide phosphate oxidase. J Immunol 
179:7720-7728. 
 111
60. el Benna, J., L. P. Faust, and B. M. Babior. 1994. The phosphorylation of the 
respiratory burst oxidase component p47phox during neutrophil activation. 
Phosphorylation of sites recognized by protein kinase C and by proline-
directed kinases. J Biol Chem 269:23431-23436. 
61. Kent, J. D., S. Sergeant, D. J. Burns, and L. C. McPhail. 1996. Identification 
and regulation of protein kinase C-delta in human neutrophils. J Immunol 
157:4641-4647. 
62. Majumdar, S., L. H. Kane, M. W. Rossi, B. D. Volpp, W. M. Nauseef, and H. 
M. Korchak. 1993. Protein kinase C isotypes and signal-transduction in human 
neutrophils: selective substrate specificity of calcium-dependent beta-PKC and 
novel calcium-independent nPKC. Biochim Biophys Acta 1176:276-286. 
63. Nixon, J. B., and L. C. McPhail. 1999. Protein kinase C (PKC) isoforms 
translocate to Triton-insoluble fractions in stimulated human neutrophils: 
correlation of conventional PKC with activation of NADPH oxidase. J 
Immunol 163:4574-4582. 
64. Reeves, E. P., L. V. Dekker, L. V. Forbes, F. B. Wientjes, A. Grogan, D. J. 
Pappin, and A. W. Segal. 1999. Direct interaction between p47phox and 
protein kinase C: evidence for targeting of protein kinase C by p47phox in 
neutrophils. Biochem J 344 Pt 3:859-866. 
65. Babior, B. M. 1995. The respiratory burst oxidase. Curr Opin Hematol 2:55-
60. 
66. Curnutte, J. T. 1993. Chronic granulomatous disease: the solving of a clinical 
riddle at the molecular level. Clin Immunol Immunopathol 67:S2-15. 
67. Dinauer, M. C. 1993. The respiratory burst oxidase and the molecular genetics 
of chronic granulomatous disease. Crit Rev Clin Lab Sci 30:329-369. 
68. Reeves, E. P., M. Nagl, J. Godovac-Zimmermann, and A. W. Segal. 2003. 
Reassessment of the microbicidal activity of reactive oxygen species and 
hypochlorous acid with reference to the phagocytic vacuole of the neutrophil 
granulocyte. J Med Microbiol 52:643-651. 
69. Henderson, L. M., and R. W. Meech. 2002. Proton conduction through 
gp91phox. J Gen Physiol 120:759-765. 
70. Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. 
Weiss, Y. Weinrauch, and A. Zychlinsky. 2004. Neutrophil extracellular traps 
kill bacteria. Science 303:1532-1535. 
71. Hirsch, J. G. 1958. Bactericidal action of histone. J Exp Med 108:925-944. 
72. Fuchs, T. A., U. Abed, C. Goosmann, R. Hurwitz, I. Schulze, V. Wahn, Y. 
Weinrauch, V. Brinkmann, and A. Zychlinsky. 2007. Novel cell death 
program leads to neutrophil extracellular traps. J Cell Biol 176:231-241. 
73. Gupta, A. K., P. Hasler, W. Holzgreve, S. Gebhardt, and S. Hahn. 2005. 
Induction of neutrophil extracellular DNA lattices by placental microparticles 
and IL-8 and their presence in preeclampsia. Hum Immunol 66:1146-1154. 
74. Steinberg, B. E., and S. Grinstein. 2007. Unconventional roles of the NADPH 
oxidase: signaling, ion homeostasis, and cell death. Sci STKE 2007:pe11. 
75. Brinkmann, V., and A. Zychlinsky. 2007. Beneficial suicide: why neutrophils 
die to make NETs. Nat Rev Microbiol 5:577-582. 
76. Jann, N. J., M. Schmaler, S. A. Kristian, K. A. Radek, R. L. Gallo, V. Nizet, 
A. Peschel, and R. Landmann. 2009. Neutrophil antimicrobial defense against 
S. aureus is mediated by phagolysosomal and extracellular trap-associated 
cathelicidin. 
 112
77. Weiner, D. J., R. Bucki, and P. A. Janmey. 2003. The antimicrobial activity of 
the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. 
Am J Respir Cell Mol Biol 28:738-745. 
78. Wartha, F., K. Beiter, B. Albiger, J. Fernebro, A. Zychlinsky, S. Normark, and 
B. Henriques-Normark. 2007. Capsule and D-alanylated lipoteichoic acids 
protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell 
Microbiol 9:1162-1171. 
79. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor 
signalling. Nature 430:257-263. 
80. Hayashi, F., T. K. Means, and A. D. Luster. 2003. Toll-like receptors 
stimulate human neutrophil function. Blood 102:2660-2669. 
81. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, 
and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced 
by binding of a tri-acylated lipopeptide. Cell 130:1071-1082. 
82. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of 
Staphylococcus aureus: epidemiology, underlying mechanisms, and associated 
risks. Clin Microbiol Rev 10:505-520. 
83. Hashimoto, M., K. Tawaratsumida, H. Kariya, K. Aoyama, T. Tamura, and Y. 
Suda. 2006. Lipoprotein is a predominant Toll-like receptor 2 ligand in 
Staphylococcus aureus cell wall components. Int Immunol 18:355-362. 
84. Hashimoto, M., K. Tawaratsumida, H. Kariya, A. Kiyohara, Y. Suda, F. 
Krikae, T. Kirikae, and F. Götz. 2006. Not lipoteichoic acid but lipoproteins 
appear to be the dominant immunobiologically active compounds in 
Staphylococcus aureus. J Immunol 177:3162-3169. 
85. Hoebe, K., P. Georgel, S. Rutschmann, X. Du, S. Mudd, K. Crozat, S. Sovath, 
L. Shamel, T. Hartung, U. Zahringer, and B. Beutler. 2005. CD36 is a sensor 
of diacylglycerides. Nature 433:523-527. 
86. Nilsen, N. J., S. Deininger, U. Nonstad, F. Skjeldal, H. Husebye, D. Rodionov, 
S. von Aulock, T. Hartung, E. Lien, O. Bakke, and T. Espevik. 2008. Cellular 
trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: 
role of CD14 and CD36. J Leukoc Biol 84:280-291. 
87. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. 
Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic 
acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates 
immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding 
protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol 
Chem 278:15587-15594. 
88. Rodriguez-Martinez, S., M. E. Cancino-Diaz, and J. C. Cancino-Diaz. 2006. 
Expression of CRAMP via PGN-TLR-2 and of alpha-defensin-3 via CpG-
ODN-TLR-9 in corneal fibroblasts. Br J Ophthalmol 90:378-382. 
89. Li, Q., A. Kumar, J. F. Gui, and F. S. Yu. 2008. Staphylococcus aureus 
lipoproteins trigger human corneal epithelial innate response through toll-like 
receptor-2. Microb Pathog 44:426-434. 
90. Takeuchi, O., K. Hoshino, and S. Akira. 2000. Cutting edge: TLR2-deficient 
and MyD88-deficient mice are highly susceptible to Staphylococcus aureus 
infection. J Immunol 165:5392-5396. 
91. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. 
Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to 
defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274:8405-
8410. 
 113
92. Peschel, A., R. W. Jack, M. Otto, L. V. Collins, P. Staubitz, G. Nicholson, H. 
Kalbacher, W. F. Nieuwenhuizen, G. Jung, A. Tarkowski, K. P. van Kessel, 
and J. A. van Strijp. 2001. Staphylococcus aureus resistance to human 
defensins and evasion of neutrophil killing via the novel virulence factor MprF 
is based on modification of membrane lipids with l-lysine. J Exp Med 
193:1067-1076. 
93. Staubitz, P., H. Neumann, T. Schneider, I. Wiedemann, and A. Peschel. 2004. 
MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important 
determinant in staphylococcal defensin resistance. FEMS Microbiol Lett 
231:67-71. 
94. Collins, L. V., S. A. Kristian, C. Weidenmaier, M. Faigle, K. P. Van Kessel, J. 
A. Van Strijp, F. Gotz, B. Neumeister, and A. Peschel. 2002. Staphylococcus 
aureus strains lacking D-alanine modifications of teichoic acids are highly 
susceptible to human neutrophil killing and are virulence attenuated in mice. J 
Infect Dis 186:214-219. 
95. Kristian, S. A., M. Durr, J. A. Van Strijp, B. Neumeister, and A. Peschel. 
2003. MprF-mediated lysinylation of phospholipids in Staphylococcus aureus 
leads to protection against oxygen-independent neutrophil killing. Infect 
Immun 71:546-549. 
96. Kristian, S. A., X. Lauth, V. Nizet, F. Goetz, B. Neumeister, A. Peschel, and 
R. Landmann. 2003. Alanylation of teichoic acids protects Staphylococcus 
aureus against Toll-like receptor 2-dependent host defense in a mouse tissue 
cage infection model. J Infect Dis 188:414-423. 
97. Jin, T., M. Bokarewa, T. Foster, J. Mitchell, J. Higgins, and A. Tarkowski. 
2004. Staphylococcus aureus resists human defensins by production of 
staphylokinase, a novel bacterial evasion mechanism. J Immunol 172:1169-
1176. 
98. Sieprawska-Lupa, M., P. Mydel, K. Krawczyk, K. Wojcik, M. Puklo, B. Lupa, 
P. Suder, J. Silberring, M. Reed, J. Pohl, W. Shafer, F. McAleese, T. Foster, J. 
Travis, and J. Potempa. 2004. Degradation of human antimicrobial peptide 
LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents 
Chemother 48:4673-4679. 
99. Nizet, V. 2007. Understanding how leading bacterial pathogens subvert innate 
immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 120:13-
22. 
100. Clements, M. O., S. P. Watson, and S. J. Foster. 1999. Characterization of the 
major superoxide dismutase of Staphylococcus aureus and its role in 
starvation survival, stress resistance, and pathogenicity. J Bacteriol 181:3898-
3903. 
101. Karavolos, M. H., M. J. Horsburgh, E. Ingham, and S. J. Foster. 2003. Role 
and regulation of the superoxide dismutases of Staphylococcus aureus. 
Microbiology 149:2749-2758. 
102. Liu, G. Y., A. Essex, J. T. Buchanan, V. Datta, H. M. Hoffman, J. F. Bastian, 
J. Fierer, and V. Nizet. 2005. Staphylococcus aureus golden pigment impairs 
neutrophil killing and promotes virulence through its antioxidant activity. J 
Exp Med 202:209-215. 
103. Cieutat, A. M., P. Lobel, J. T. August, L. Kjeldsen, H. Sengelov, N. 
Borregaard, and D. F. Bainton. 1998. Azurophilic granules of human 
neutrophilic leukocytes are deficient in lysosome-associated membrane 
 114
proteins but retain the mannose 6-phosphate recognition marker. Blood 
91:1044-1058. 
104. Dahlgren, C., S. R. Carlsson, A. Karlsson, H. Lundqvist, and C. Sjolin. 1995. 
The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in 
mobilizable organelles, but are absent from the azurophil granules of human 
neutrophils. Biochem J 311 ( Pt 2):667-674. 
105. Bainton, D. F. 1999. Distinct granule populations in human neutrophils and 
lysosomal organelles identified by immuno-electron microscopy. J Immunol 
Methods 232:153-168. 
106. Letiembre, M., H. Echchannaoui, P. Bachmann, F. Ferracin, C. Nieto, M. 
Espinosa, and R. Landmann. 2005. Toll-like receptor 2 deficiency delays 
pneumococcal phagocytosis and impairs oxidative killing by granulocytes. 
Infect Immun 73:8397-8401. 
107. Yang, C. S., D. M. Shin, H. M. Lee, J. W. Son, S. J. Lee, S. Akira, M. A. 
Gougerot-Pocidalo, J. El-Benna, H. Ichijo, and E. K. Jo. 2008. ASK1-p38 
MAPK-p47phox activation is essential for inflammatory responses during 
tuberculosis via TLR2-ROS signalling. Cell Microbiol 10:741-754. 
108. Urban, C. F., U. Reichard, V. Brinkmann, and A. Zychlinsky. 2006. 
Neutrophil extracellular traps capture and kill Candida albicans yeast and 
hyphal forms. Cell Microbiol 8:668-676. 
 
 
 115
Acknowledgements 
First, my cordially felt gratitude goes to my thesis supervisor Prof. Dr. Regine 
Landmann for the opportunity to do my PhD in her lab and the guidance of my thesis. 
Your professional and personal support guided my training as a scientist and provided 
me the opportunity to extend my practical skills and develop my own ideas. 
Furthermore, I could always benefit of your experience in the field of immunology 
and medicine, which complemented my microbiological perception and endowed me 
with a profound knowledge for my future career. Second, I would like to thank Prof. 
Dr. Guy Cornelis and Prof. Dr. Dirk Bumann for taking the part of my thesis 
committee. 
I owe great gratitude to the members of our lab for the support and assistance in my 
project and the enjoyable atmosphere in the lab. Fabrizia Ferracin for your technical 
assistance in my project, but also special thank for the numerous coffee breaks, 
“Znüni”-moments and relaxing chats. Zarko Rajacic for the practical education in 
animal experiments and the helping hand when time was short. I thank my colleagues, 
Mathias Schmaler and Hatice Karaüzüm, for your critical and often imaginative 
scientific inputs to my project. I thank Hati for the times outside the lab in bars or at 
home with delicious Turkish food and for always having an open ear. Special thank to 
Mathias, your invaluable friendship supported me when I was disillusioned. I will 
never forget the pleasant evenings we spent out together talking about our hopes and 
fears. I also like to thank Anne-Kathrin John for taking care of me and my health with 
her happiness, sports and vitamins; Richard Kühl and Oliver Gordon for the short but 
funny time we spent together in the lab and drinking beer in bars. Without the help 
and friendship of you all, this thesis would never have come to an end. 
 116
Mein innigster Dank gilt meinen lieben Eltern, Alice and Heinz Jann. Euer Glaube 
und euer Vertrauen und eure unendliche Liebe gaben mir die Stärke und das 
Selbstvertrauen meine Ziele zu verfolgen. Auch in schweren Zeiten und wenn Tränen 
flossen waren eure Arme immer offen und gaben Hoffnung, Halt und Trost. Ihr habt 
mir meine Träume ermöglicht und ich hoffe, dass ich euch eines Tages zurückgeben 
kann, was ihr für mich getan habt. I especially thank my boyfriend Felix Nyffenegger. 
Your love and appreciation gave me comfort and confidence in the last four years. It 
often was a hard time with lots of tears for you to dry and arguments to bear. But you 
always caught me when I was falling and brought me back to happiness. It was your 
inexpressible love and your strong belief in me that let me reach my dreams. My dear 
brother Kay, you won our familial competition by a narrow margin of 4 days, 
congratulations! Nevertheless, thank you for driving me forwards during the time at 
ETH and of PhD thesis and I will always be proud of my big brother. Finally, great 
thank goes to my dearest friends, the microbiologists and the engineers, for countless 
days and nights spent in the world outside my thesis recovering my energy. 
  117
Curriculum Vitae 
 
Naja Jann, PhD 
Gotthardstrasse 37 
4054 Basel  
Switzerland  
e-mail: naja.jann@unibas.ch  
 
 
 
Personal Information 
 
Surname, first name Jann, Naja 
 
Business address Infection Biology 
 Department of Biomedicine 
 University Hospital Basel 
 Hebelstrasse 20 
 4031 Basel 
 Phone: 0041 61 265 23 66 
 e-mail: naja.jann@unibas.ch 
 
Date of birth April 16th 1981 
Place of birth Rorschach (SG), Switzerland 
Nationality Swiss 
Home towns Balgach and Rebstein (SG), Switzerland 
 
 
Education 
 
04/2005 – 03/2009 PhD thesis at the Division of Infection Biology, Department 
of Biomedicine, University Hospital Basel, Basel, 
Switzerland 
Prof. Dr. R. Landmann 
 
2003 - 2004 Diploma thesis: „Inhibition of Shigella-induced Apoptosis by 
the Ionophore CCCP“ 
Institute of Microbiology, ETH, Zurich, Switzerland 
Prof. Dr. H. Hilbi  
 
2003 Semester thesis: “Protection of Macrophages of Shigella-
induced Apoptosis” 
Institute of Microbiology, ETH, Zurich, Switzerland 
Prof. Dr. H. Hilbi,  
 
10/2000 – 11/2004 Swiss Federal Institute of Technology (ETH), Zurich, 
Switzerland 
Diploma in biology at the Department of Biology (D-BIOL) 
Branch of study: Microbiology 
 
  118
1996 - 2000 Kantonsschule Heerbrugg, Heerbrugg (SG), Switzerland 
Matura Typus C (Mathematics, Natural Sciences) 
 
 
Work Experience 
 
February 2006 Introductory Course in Laboratory Animal Science (mouse, 
rat, guinea pig, rabbit) organized by the Institute of 
Laboratory Animal Sciences, University of Zurich 
 
11/2004 – 01/2005 Research assistant, Thurgauer Namenbuch 
Kreuzlingen (TG), Switzerland 
 
02/2002 – 04/2002 Substitute teacher in mathematics 
Kantonsschule Heerbrugg (SG), Switzerland 
 
 
Congress Participation 
 
2008 41st Annual Meeting of the Society of Leukocyte Biology, 
Leukocytes: Tissue Interactions, Homeostasis, and Host 
Defense, Denver (CO), United States 
Nomination for „Presidential Student Awards“ 
(oral presentation) 
Recipient of „Student Travel Award“ 
 
2008 Toll 2008 Recent Advances in Pattern Recognition, Cascais, 
Portugal 
(poster presentation) 
 
2007 6th Gordon Research Conference on Antimicrobial Peptides, 
Il Ciocco, Lucca (Barga), Italy 
(oral and poster presentation) 
 
2006 20th Annual Meeting of the European Macrophage and 
Dendritic Cell Society, Immunoregulatory and Antimicrobial 
Activities of Myeloid Cells, Freiburg, Germany, 
(poster presentation) 
 
2006 12th International Symposium on Staphylococci and 
Staphylococcal Infections, Maastricht, The Netherlands 
(poster presentation) 
 
  119
 
Publication List 
 
Schroeder GN, Jann NJ, Hillbi H 
„Intracellular type III secretion by cytoplasmic Shigella flexneri promotes caspase-1-
dependent macrophage cell death“ 
Microbiology. 2007 Sep; 153:2862-76 
 
Schmaler M, Jann NJ, Ferracin F, Landolt LZ, Biswas L, Götz F, Landmann R 
„Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-
dependent growth in vivo“ 
The Journal of Immunology. 2009 Jun; 182(11):710-8 
 
Jann NJ, Schmaler M, Kristian S, Radek K, Nizet V, Gallo R, Peschel A, Landmann R 
„Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by 
phagolyosomal but not extracellular trap-associated cathelicidin“ 
(Accepted by The Journal of Leukocyte Biology, June 2009) 
 
Jann NJ, Schmaler M, Kristian S, Radek K, Nizet V, Gallo R, Peschel A, Landmann R 
„Role of TLR2 in non-oxidative and oxidative killing mechanisms of PMN against 
Staphylococcus aureus“ 
(Manuscript in preparation. 2009) 
 
